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Riassunto  
La Sclerosi Multipla (SM) è una patologia infiammatoria autoimmune cronica, 
disabilitante e demielinizzante, del sistema nervoso centrale (SNC). La 
migrazione di cellule T autoreattive e la loro riattivazione attraverso la 
presentazione antigenica effettuata dalle locali cellule presentanti l’antigene, 
rappresentano due eventi critici nella patogenesi della SM e nel suo modello 
animale, l’encefalite autoimmune sperimentale (EAE). Le risposte ai potenziali 
antigeni all’interno del SNC richiedono una migrazione a lungo raggio, 
comunicazione a corto raggio e contatti cellula-cellula diretti con le cellule 
presentanti l’antigene.  
Il principale obiettivo di questo studio è indagare il ruolo delle integrine aLb2 
(LFA-1) e a4 (VLA-4 and a4b7) nella migrazione e nella motilità delle cellule 
autoreattive Th1 e Th17 in corso di EAE all’interno del midollo spinale 
utilizzando le moderne tecniche di microscopia intravitale.  
La microscopia intravitale permette di visualizzare questi processi dentro il 
midollo spinale, il quale rappresenta il principale sito di infiammazione durante 
l’EAE. Mediante la microscopia intravitale in epifluorescenza abbiamo prima di 
tutto investigato il ruolo delle integrine a4 e LFA-1 nella migrazione delle cellule 
autoreattive Th1 e Th17 all’interno dei vasi piali del midollo spinale durante la 
fase preclinica, l’esordio e la fase cronica di EAE. Abbiamo utilizzato un modello 
di EAE immunizzando topi C57BL/6 con il peptide MOG35-55. Le cellule Th1 e 
Th17 MOG-specifiche sono state prodotte in vitro da topi TCR-transgenici 2D2, 
marcate con label fluorescenti e iniettate in endovena nei topi immunizzati 
direttamente prima dell’acquisizione.  
I nostri risultati pongono l’accento su un ruolo selettivo per l’integrina LFA-1 
nella migrazione delle cellule Th1 in particolare durante le prime fasi di malattia. 
Ruolo che invece non è svolto in fase cronica di malattia. 
Inoltre, il blocco della subunità a4, ma non dell’integrina a4b7 inibisce 
fortemente sia il rotolamento sia l’adesione stabile delle cellule Th1 all’endotelio 
infiammato. Questo suggerisce l’integrina VLA-4 come principale mediatrice 
della migrazione delle Th1 nel SNC infiammato in corso di EAE. Di notevole 
interesse è inoltre il selettivo ruolo per l’integrina a4b7 evidenziato in particolare 
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nell’adesione stabile esclusivamente delle cellule Th17 all’esordio ed in fase 
cronica di malattia. 
Successivamente, per studiare la motilità intraparenchimale delle cellule Th1 e 
Th17 nel midollo spinale durante la fase preclinica della patologia, il picco di 
malattia e la fase cronica abbiamo utilizzato la microsocopia laser a due fotoni.  
I nostri risultati dimostrano una massiva infiltrazione di Th1 e Th17 nel 
parenchima del SNC al picco di malattia, mentre la migrazione di queste cellule 
durante le altre fasi della malattia è significativamente minore. 
In seguito, il nostro studio si è focalizzato sulla fase clinica della malattia e 
abbiamo osservato che le cellule Th1 e le cellule Th17 mostrano differenze 
significative nelle componenti direzionali, con le cellule Th1 che si muovono 
velocemente in direzione rettilinea, coprendo lunghe distanze nel parenchima del 
midollo spinale, mente le cellule Th17 girano intorno in un volume specifico del 
tessuto facendo stop and go. In particolare, il blocco dell’integrina LFA-1 
influenza drasticamente le dinamiche delle cellule, portando ad una riduzione 
nella velocità e interferendo con il loro pattern di motilità rettilinea.  Inoltre, in 
presenza di un anticorpo bloccante anti-LFA-1, le cellule Th17 mostrano una 
riduzione di velocità drastica. Diversamente, l’anticorpo anti-a4 non ha nessun 
effetto sul comportamento motile delle Th1, ma riduce fortemente la velocità delle 
Th17 suggerendo che l’integrina VLA-4 non sia richiesta per la motilità 
intraparenchimale durante l’EAE. Tuttavia, alla luce dei risultati ottenuti in 
precedenza mediante microscopia intravitale, va preso in considerazione un 
selettivo ruolo esercitato dall’integrina a4b7 nella motilità intraparenchimale 
delle Th17. Complessivamente, i nostri risultati suggeriscono che l’LFA-1 sia la 
principale integrina che controlla la motilità delle cellule Th1 e Th17 e che a4b7 
sia invece selettivamente coinvolta nella motilità delle cellule Th17 nel midollo 
spinale in condizioni infiammatorie al picco di malattia. A sostegno di questi 
risultati abbiamo testato un trattamento terapeutico mediante blocco locale, a 
livello intratecale, delle integrine LFA-1 e a4b7 nel nostro modello murino di 
EAE cronica. Entrambi i trattamenti hanno evidenziato una riduzione nello 
sviluppo della malattia che suggerisce l’importanza di interferire direttamente con 
le dinamiche delle cellule pro infiammatorie a livello del SNC.  
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Approfondire dunque la conoscenza dei meccanismi molecolari che controllano la 
motilità intratissutale di cellule T attivate nel SNC potrebbe aiutarci a identificare 
nuove strategie terapeutiche per le patologie autoimmuni cerebrali croniche. 
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Abstract 
Multiple sclerosis (MS) is a chronic disabling autoimmune inflammatory 
demyelinating disease of the central nervous system (CNS). The migration of 
autoreactive T cells from the blood into the CNS and their reactivation through 
antigen presentation by local antigen presenting cells (APCs) represent critical 
events in the pathogenesis of MS and its animal model, the experimental 
autoimmune encephalomyelitis (EAE). The responses to potential antigens inside 
the CNS require long-range migration of cells, short-range communication and 
direct cell-cell contact with APCs. 
The main goal of this study was to investigate the role of aLb2 (LFA-1) and a4 
(VLA-4 and a4b7) integrins in the migration and motility behavior of Th1 and 
Th17 cells, which represent key players in the induction of EAE, using intravital 
microscopy approaches. 
Intravital microscopy techniques allow the visualization of T cell migration and 
reactivation in the spinal cord (SC), which represents the main inflammation site 
during EAE. By using epifluorescence intravital microscopy (IVM) we first 
studied the roles of a4 and LFA-1 integrins in Th1 and Th17 cell adhesion in the 
pial vessels of spinal cord (SC) venules in mice immunized with MOG35-55 peptide 
during the preclinical phase, disease onset and chronic phase of disease. We used 
an EAE model by immunization of C57BL/6 mice with MOG35-55 peptide. 
MOG35-55-specific Th1 and Th17 cells were produced in vitro from 2D2 TCR 
transgenic mice, labeled with fluorescent dyes and intravenously injected in 
immunized mice before imaging. Our results underlined a selective role for LFA-
1 integrin in Th1 cell recruitment in inflamed SC vessels during the early phases 
of the disease but not during the chronic phase. Moreover, blocking antibodies 
against the a4 subunit, but not blockade of a4b7 integrin greatly inhibited 
rolling and firm adhesion of Th1 cells in the SC venules during all disease phases, 
suggesting that VLA-4 is the major molecule involved in Th1 cell adhesion in the 
SC venules during EAE. Interestingly, blockade of a4b7 integrin led to a 
significant reduction of firm adhesion in Th17 cells at the onset and chronic phase 
of EAE indicating a selective role of a4b7 integrin in the recruitment of Th17 
cells in the inflamed CNS.  
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Taking advantage of two-photon laser microscopy (TPLM) approach we next 
investigated the motility behavior of fluorescently labeled Th1 and Th17 cells 
within SC parenchyma during different disease phases. Our results showed a 
massive infiltration of Th1 and Th17 cells in the CNS parenchyma at disease 
peak, whereas the migration of these cells during other phases of disease was 
significantly lower. Furthermore, Th1 and Th17 cells displayed significant 
differences in the directional component, with Th1 cells moving faster in straight 
directions covering long distances deep in the SC parenchyma, whereas Th17 
cells moved around in a specific volume of tissue in a stop and go mode. Notably, 
the blockade of LFA-1 integrin drastically affected the dynamics of Th1 cells 
leading to a reduction in velocity and interfering with their straight-line motility 
pattern. Moreover, Th17 cells displayed a drastic reduction of velocity in the 
presence of a blocking anti-LFA-1 antibody. The analysis of cellular morphology 
suggested that LFA-1 is actively involved in the cytoskeleton rearrangements 
necessary for T cell amoeboid migration inside the CNS, but had no role in the 
cytoskeleton dynamics in Th17 cells. Notably, a4 integrins had no role in Th1 
cells motility, but drastically reduced the dynamics of Th17 cells inside the SC 
parenchyma. To check the therapeutic relevance of our intravital microscopy 
findings, we performed intrathecal injection of anti-LFA-1 or anti-a4b7 
antibodies at disease onset and observed a significant inhibition of EAE 
progression in mice immunized with MOG35-55 peptide. Collectively, our data 
demonstrate that LFA-1 integrin differently controls intraparenchymal Th1 and 
Th17 cells dynamics, whereas a4b7 integrin is selectively involved in Th17 cell 
trafficking in the CNS during EAE. Furthermore, our results suggest that 
interfering with the molecular mechanisms controlling intraparenchymal 
dynamics of activated T cells may represent a new therapeutic strategy for CNS 
autoimmune diseases. 
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Introduction 
 
Multiple sclerosis: the history of a disease 
Multiple sclerosis (MS) is a chronic, often disabling autoimmune inflammatory 
disorder of the nervous system (CNS) mostly affecting the young adult 
population. Jean-Martin Charcot, neurologist at the Hôpital de Salpétrière, well 
defined for the first time the features of MS, as “le sclérose en plaque”, in 1868 
(Orrell RW, J R Soc Med 2005). MS is a disease affecting approximately 2.5 
million people worldwide, counting 250,000 to 400,000 people in the United 
States (Noonan CW et al., Neurology, 2002; Ascherio A and Munger K, Semin 
Neurol, 2008) and similar rates in Europe (Pugliatti M et al., Eur J Neurol, 2006). 
As is in the case of many other autoimmune diseases, evidence suggests that the 
incidence of MS is increasing (Orton SM et al., Lancet Neurol, 2006).  
The disease most often starts between 20 and 40 years of age, and affects women 
more frequently than man (Compston A and Coles A, Lancet, 2008). MS can 
follow different patterns of evolution and varying rates of disability. In 1996, the 
US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical 
Trials defined the clinical subtypes of MS and provided standardized definitions 
for four MS clinical course: relapsing-remitting (RR), secondary progressive (SP), 
primary progressive (PP) and progressive relapsing (PR) At disease onset, 80% of 
patients show an acute episode affecting one or several sites, which is known as 
the clinically isolated syndrome (CIS), while 20% of patients display primary 
progressive MS (PPMS). This initial transient inflammation in CIS leads to 
successive episodes of neurological dysfunction (this form of disease is called 
relapsing-remitting MS, RRMS) at the early course of disease that usually recover 
and transient remyelination occurs. If these episodes were accompanied by 
whitematter abnormalities detected by magnetic resonance imaging (MRI) at 
clinically unaffected sites, the chance of a second attack of demyelination 
subsequently recurring, accomplishing the diagnostic criteria for relapsing-
remitting multiple sclerosis. Over time symptoms accumulate leading to chronic 
progressive disability for the majority of people with the disorder (Fig. 1). 
Progressive forms of MS are associated with gradual loss of neurological function 
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and ascending paralysis and are thought to be in part independent of 
inflammation. In all these situations, progression starts at around 40 years of age. 
Although MS occurs most commonly in young adults, it is also diagnosis in 
children and adolescents. They take more years to reach from onset the secondary 
progressive stage than adults, but anyhow do so at a younger age. In all disease 
forms, the clinical course takes several decades to evolve (Confravreux C and 
Vukusic S, Brain 2005; Compston A and Coles A, Lancet 2008).  
RRMS, which is the most common form of MS, is associated with acute 
inflammatory episodes resulting in a reduction in neurological function. Patients 
may experience some recovery between relapses, but the majority of patients with 
RRMS evolve to a more progressive form, termed secondary progressive MS 
(SPMS), which is associated with gradual loss of neurological function and 
ascending paralysis and is thought to be independent of inflammation.  
Figure. 1 Progression of multiple sclerosis. Different risk factors play a role 
during subclinical phase of disease triggering CNS inflammation (red area). 
Progression of MS takes several years (green area). Bars denote inflammatory 
events that cause damage to CNS, although some of which do not achieve clinical 
thresholds. Arrows show episodes of new inflammation detected by MRI, that 
results more frequent than clinical relapses (Picture adapted from Olsson T et al., 
Nat Rev Neurol, 2016). 
 
MS is characterized by perivascular infiltration of mononuclear cells that includes 
lymphocytes and macrophages (Prineas JW, Handbook of Multiple Sclerosis, 
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1996). These inflammatory plaques, determined using magnetic resonance 
imaging (MRI), represent the pathological hallmark of MS (Frohman et al., N 
Engl J Med, 2006). 
Although the precise etiology of MS remains not well understood and 
environmental factors are still unknown, recently the identification of genetic 
variants affecting the development of the disease has grown almost exponentially. 
The cause of the recurrent inflammation in MS is now generally accepted to be 
autoimmune in nature. Studies demonstrating the presence of inflammatory cells 
and their products in the brain lesions of MS patients, in addition to reports from 
animal models, has led to the generally accepted hypothesis that disease is 
mediated by pathogenic T cell responses against myelin antigens, followed by a 
broader neurodegenerative process (Compston A and Coles A, Lancet, 2008). 
Leucocyte infiltration from peripheral circulation through the blood-barrier brain 
(BBB) causes the activation of microglia and astrocytes leading to the myelin 
sheath and the underlying axon damage. 
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Multiple sclerosis: the pathogenesis from peripheral side to the central nervous 
system 
The pathogenesis leading to demyelination includes 3 major processes. The first 
step is establishment of autoimmunity to CNS myelin components, in which 
molecular mimicry between infectious agents and myelin antigens may play a role 
(Wucherpfenning KW and Strominger JL, Cell, 1995) (Fig. 2).  
Figure 2. Pathogenesis of MS: the story begins on the peripheral side. 
Principal processes in the development of EAE or MS occur in a peripheric 
dysregulated immune system: once activated, autoreactive CD8+, CD4+ T cells 
such as Th1 and Th17 cells, B cells and innate immune cells can egress from 
lymphoid tissues and then migrate to the CNS. Genetic, life style and enviroment 
are risk factors in MS (Picture adapted from Dendrou C et al., Nat Rev Immunol, 
2015) 
 
The second step is the entry of immune cells into the CNS via the BBB. The third 
step consists of immune reactions occurring within the CNS when activated T 
cells encounter specific antigens presented by microglia. T helper (Th) cells, so 
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called for their ability to coordinate and fine-tune the immune response, initiate an 
attack against “self” antigens expressed mainly on oligodendrocytes leading to 
chronic inflammation (Comabella M and Khoury SJ, Clinical Immunology, 2012). 
Final demyelination is rendered either by macrophages recruited from the 
bloodstream across the BBB, or by tumor necrosis factor (TNF)-α and nitric oxide 
(NO), which are secreted by T cells and macrophages, and toxic to CNS myelin 
(Fig. 3). The inflammatory processes of MS are associated with a complex 
cascade of inflammatory molecules and mediators, including chemokines, 
adhesion molecules associated with activated endothelium of vessels wall and 
matrix metalloproteases (Cannella B and Raine CS, Ann. Neurol, 1995; Cuzner 
ML, Neuropathol Exp Neurol, 1996; Sørensen TL et al., J Clin Invest, 1999). 
 
 
Figure 3. Pathogenesis of MS: what happens on the CNS side. Infiltration of 
immune cells from the periphery primarily occurs during early-stage of disease. 
Infiltrating cells can pass from the meningeal blood vessels through the BBB or 
the subarachnoid space or from the choroid plexus across the blood cerebrospinal 
fluid (CSF). Within CNS parenchyma these cells and activated resident microglia 
and astrocytes lead to demyelination and neuroaxonal injury with direct cell-
contact mechanisms and the release of soluble inflammatory factors and 
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neurotoxic mediators (Picture adapted from Dendrou C et al., Nat Rev Immunol, 
2015).  
 
Leukocyte recruitment to sites of inflammation is the “primu movens” of the 
immune responses and consists of a multistep process regulated by adhesion 
molecules and chemoattactants. Classically, leukocyte adhesion cascade includes 
three main steps including rolling, activation and firm adhesion to the endothelia. 
The first contact between leukocyte and endothelial cells is named tethering, 
followed by rolling, which occurs as subsequent interaction. Among adhesion 
molecules, selectins and their carbohydrate ligands are associated with tethering 
and rolling steps. Rolling is mediated by E-selectin P-selectin and L- selectin 
which have as dominant ligand the P-selectin glycoprotein ligand (PSGL-1) for all 
three selectins. PSGL-1 is expressed on almost all leukocytes and certain 
endothelial cells. In addition to PSGL-1, E-sel binds to glycosylated CD44 (Ley K 
et al., Nat Rev Immunol, 2007). The adhesion molecule CD44 and the interaction 
with its main ligand the hyaluronic acid (HA), have also received attention in 
recent studies, in particular during autoimmune disease and cancers. As a primary 
adhesion receptor, CD44 can mediate leukocyte rolling on activated endothelium 
and extravasation. Moreover, CD44 may have a role in cell-matrix interactions, in 
particular can guide localization of cells within inflamed tissue (Puré E and Cuff 
CA, Trends Mol Med, 2001). Also a4 integrins may support the rolling step. 
Indeed, integrin activation triggered by chemoattractants is well acknowledged as 
key event in leukocytes arrest in blood vessels, but they also play a role during 
leukocyte rolling. Integrin activation requires a G-protein-coupled receptor 
engagement with an appropriate chemoattractant and include both clustering on 
cell membrane and modulation of the integrin conformation leading to reach a 
state of high affinity for binding to integrin endothelial counter receptor. Finally, 
the extravasation of leukocytes, also referred as diapedesis, depends on 
cytoskeleton rearrangement and represents the final step of the recruitment 
process (Ransohoff RM et al., Nat Rev Immunol, 2003; Ley K et al., Nat Rev 
Immunol, 2007).  
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Integrin family  
Integrins are a large family of heterodimeric transmembrane glycoproteins 
composed of nonhomologous α and β transmembrane proteins of 100 kDa. 
Structurally, a large extracellular domain form a globular head in which sticks to a 
pair of short cytoplamatic tails connect each subunit. The a and b subunits are 
characterized by a large extracellular domain, a short transmembrane domain and 
a cytoplasmic region. The association of both subunits at N-terminal end forms 
the ligand-binding site, whereas the C-terminal region traverses the plasma 
membrane and interacts with cytoskeleton. The ligand-binding activity can be 
rapidly regulated by conformational changes as well as by transcriptional 
induction and redistribution from intracellular pools (Carman CV and Springer 
TA, Curr Opin Cell Biol, 2003). Integrin functions as bi-directional signaling 
molecules and binding to their ligands results in intracellular signals and 
conversely, cellular signaling events can modulate their affinity for extracellular 
ligands. 
The most important β1-integrin expressed on leukocytes is the Very Late Antigen-
4 (VLA-4, CD49d/CD29, α4β1), which binds to its ligand VCAM-1 (CD106), 
and is chiefly responsible for leukocyte rolling and firm adhesion to vascular 
endothelium and leukocyte recruitment to the inflamed area (Luster AD et al., Nat 
Immunol, 2005; Ley K et al., Nat Rev Immunol, 2007). β2-integrins include four 
different heterodimers: Lymphocyte Function-Associated Antigen-1 (LFA-1, 
CD11a/CD18), Mac-1 (CD11b/CD18), p150, 95 (CD11c/CD18), and 
CD11d/CD18. The most studied β2-integrin involved in leukocyte recruitment is 
LFA-1 (CD11a/CD18; αLβ2) which participates in rolling interactions but 
predominantly mediates the firm adhesion/arrest of leukocytes in the blood 
vessels of lymphoid organs or at sites of inflammation by binding the Ig 
superfamily ligands ICAM-1 (CD54) and ICAM-2 (CD102), expressed by the 
vascular endothelium (Luster AD et al., Nat Immunol, 2005; Ley K et al., Nat Rev 
Immunol, 2007).  
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LFA-1 integrin  
LFA-1 has a heterodimeric structure with two subunits: CD18, which is common 
at all β2-integrins and CD11a, which is specific for LFA-1. As circulating 
leukocytes are continually exposed to ICAMs on the vasculature, therefore the 
ligand-binding activity of LFA-1 has to be kept under tight control to avoid 
inappropriate adhesion while these cells are flowing in blood or migrating through 
tissues and thus needs to be highly regulated. Integrin activation is achieved by 
signaling through other leukocyte receptors, termed “inside-out signaling”. 
“Outside-in signaling” is generated when the active integrin signals back into the 
leukocyte on which it is expressed. 
LFA-1 is found in three distinct conformational states (Fig. 4). The inactive low-
affinity state shows a bent structure with the ligand-binding headpiece (αI 
domain) in close proximity to membrane-proximal stalk region. In the 
intermediate affinity state LFA-1 starts to extend the stalk regions shifting the 
molecule to the active higher-affinity conformation, where LFA-1 exhibits 
extended extracellular domain with the ligand-binding pocket for ICAM-1. 
 
 
 
Figure 4. LFA-1 conformations. Three different conformations of LFA-1 
integrin have been demonstrated. LFA-1 is in low affinity state extracellular 
domain with a bent structure shaped like an inverted V (left). Extended 
conformations (middle) have a different orientation of their hybrid domain 
(purple). The swingout of this domain lead to the conversion from intermediate to 
high affinity state (right) (Picture adapted from Lefort CT and Ley K., Front 
Immunol, 2012). 
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Several studies reported that the active conformation causes integrin activation 
allowing matrix interactions and mediating firm arrest on endothelium. A number 
of structural studies in recent years have provided better understanding of how 
signals may be transmitted from the intracellular integrin domains across the cell 
membrane to the ligand-binding domain. Two major modulation of integrin 
functions have been demonstrated, involving (1) increased receptor affinity by 
conformational changes of the heterodimer or (2) lateral mobility of the receptor 
on the plasma membrane leading to formation of clusters of heterodimers and 
increased avidity (Bazzoni G and Hemler ME, Trends Biochem Sci, 1998). For T 
cells, clustering appears to be the consequence of an initial high-affinity 
interaction of LFA-1 with multivalent ICAM-1. Clustering formation leads to 
cytoskeletal rearrangements that are essential for the adhesion and spreading of T 
cells on ICAM-1 (Porter JC et al., J Immunol, 2002). Moreover, once the T cell 
begins to migrate, the distribution of the membrane LFA-1 is changed. LFA-1 is 
organized into at least three different regions of activity in the migrating cell: the 
projecting lamellae at the leading edge where intermediate affinity LFA-1 
functions, the mid cell zone containing high-affinity LFA-1, and the elevated 
uropod at the trailing edge with its high levels of LFA-1. More likely, the mid cell 
zone provides firm attachment to ICAM-1 that supports the cell’s extensive 
leading edge as it scans other leukocytes and vascular surface. The membrane 
organization of LFA-1 into intermediate and high-affinity zone gives biological 
relevance to these different conformations and suggests that they operate together 
to regulate migration. 
The ability of T cells to adhere and migrate is critical for a fully functional 
immune system. In response to inflammatory signals, T cells leave the blood 
stream by migrating along vascular endothelial surfaces, scanning for a suitable 
exit point into target tissue (Serrador J et al., Trends Cell Biol, 1999; Worthylake 
RA and Burridge K, Curr Opin Cell Biol, 2001). In vitro T cells are observed to 
move across the surface of APCs in a state of constant motility (Friedl P and 
Gunzer M, Trends Immunol, 2001), and in vivo T cells are highly motile deep in 
the lymph nodes (Miller MJ et al., Proc Natl Acad Sci, 2003) or in the inflamed 
target tissue such as in the SC during EAE (Bartholomäus I et al., Nature, 2009). 
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The ability of LFA-1 to act as a signaling receptor has not been extensively 
examined, as it has been chiefly associated with promoting cell-cell contacts, 
thereby optimizing signaling through other receptors. Cells move by coordinating 
the generation of lamellipodial protrusions at the front of the cell leading to new 
attachments, followed by the detachment of previous adhesions at the rear of the 
cell (Horwitz AR and Parson JT, Science 1999). LFA-1 is directly involved in 
leading to cell attachment, polarization and random migration. These events are 
critically dependent on dynamic changes in the acto-myosin cytoskeleton.  
Even though an active role of LFA-1 in the cytoskeleton rearrangement during 
cellular migration was established, a potential role of a4 integrin in the cell 
plasticity during migration is still not well unknown. α4 integrin cytoplasmic 
domain is known to regulate cytoskeletal association and resistance to shear stress 
during adhesion event but their role in cellular migration was not established 
(Hyduk SI et al., J Immunol, 2011; Alon R et al., J Cell Biol, 2005). 
 
Experimental animal model of multiple sclerosis and its features 
The most widely used animal model of MS is experimental autoimmune 
encephalomyelitis (EAE) (Zamvil SS and Steinman L, Annu Rev Immunol, 1990; 
Gold R et al., Brain, 2006). EAE can be induced by immunization of susceptible 
experimental animal strains including primates and rodents with myelin 
autoantigens emulsified in complete Freund’s adjuvant (CFA) or by adoptive 
transfer of brain antigen-specific T cells (Ben-Nun A et al., Eur J Immunol, 1981). 
This model was introduced by Rivers in the 1930 (Rivers TM and Schwentker FF, 
J Exp Med, 1935) and was substantially improved as an animal model for 
demyelinating inflammation of the CNS by adding Freund’s adjuvant to emulsify 
myelin antigens (Kabat EA et al., Science, 1946). 
A conceptual breakthrough was achieved in the 1980s by the groups of Wekerle 
and Cohen, who showed that myelin antigen-specific CD4+ T cell lines 
propagated in vitro could, upon adoptive transfer, induce demyelinating 
inflammation in the CNS parenchyma (Ben-Nun A et al., Eur J Immunol, 1981). 
This proved that EAE is induced by an autoimmune response to myelin antigens 
initiated by CD4+ T cells. In the following years, EAE became an invaluable tool 
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to study the activation of autoreactive T cells in the peripheral immune 
compartment, their migration into the CNS and their reactivation, and subsequent 
inflammation in the target tissue (Fig. 2, 3). In murine and primate EAE models, 
major immunogenic and encephalitogenic CNS autoantigens have been identified 
by isolation of antigen-specific major histocompatibility complex class II-
associated peptides (MHC-II) restricted T cell clones. Most of these autoantigens 
are myelin antigens such as myelin basic protein (MBP), proteolipoprotein (PLP), 
myelin oligodendrocyte glycoprotein (MOG), and myelin-associated 
oligodendrocyte basic protein (MOBP) (Gold R et al., Brain, 2006). 
Currently, the most common protocol for EAE induction is based on the injection 
of an encephalitogenic peptide, mostly MOG35-55 or PLP139-151 peptide, which is 
emulsified in CFA containing mineral oil and Mycobacterium tubercolosis strain 
H37Ra, followed by injection of pertussis toxin. The resulting phenotype depends 
mainly on the antigen source and the genetic background of the animal species 
and strains used (Fig. 5). For example, PLP139-151 peptide induces a relapsing-
remitting EAE in SJL mice, with acute disease episodes followed by a remission 
phase (Fig. 5A). The grade of remission depends on disease severity: if mice 
develop a mild disease, remission can be complete, otherwise remission could be 
partial. Typically, several acute relapses and remission phases take place during 
disease progression. 
MOG35-55 peptide, instead, triggers chronic-progressive EAE in C57Bl/6 mice that 
are the most favored mice for transgenic experiments (Gold R et al., Brain, 2006). 
C57Bl/6 mice typically develop a chronic form of the disease: after an initial 
peak, they partially recover and maintain a stable lower clinical score during 
disease chronicity (Fig. 5B). 
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Figure 5. The resulting phenotype of disease. Comparison of disease 
progression between SJL and C57Bl/6 mice. 
 
 
Helper T cells differentiation and functions during adaptive immune response 
and autoimmunity  
Naïve CD4+ T cells, after being activated by antigen presentation and 
differentiated into distinct effector subsets, play a major role in mediating immune 
response through the secretion of subset-specific cytokines. Different types of 
cellular immune responses that have been identified are essential to understanding 
the mechanisms of the inflammatory process in MS and to devising strategies to 
control it. Depending on the cytokines they produce, these T cell subsets have 
very different properties. Helper T cells (Th cells) include the well-defined 
effector Th1, Th2 and Th17 subsets as well as the more recently described Th22 
cells, but also regulatory subsets like regulatory T cells (Treg) (Fig. 6). Three 
signals are required for efficient T cell differentiation. The first is in the form of 
antigen presented by an antigen- presenting cell (APC), such as a dendritic cell 
(DC). The second signal comes in the form of costimulatory receptors on T cells 
engaging their cognate ligands on APCs. Small signaling protein molecules, such 
as cytokines, provide the third signal (Kapsenberg ML, Nature Reviews 
Immunology, 2003). Antigen presentation in the presence of interleukin (IL)-12 
induces the expression of T-bet and production of interferon (IFN)-g, therefore 
promoting naïve T cell polarization into the Th1 phenotype (Fig. 6). Th1 
phenotype cell targets are macrophages and dendritic cells. Th1 type responses are 
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important in inflammation and tissue injury. IL-4 induces GATA3 expression and 
IL-4 production and is necessary for Th2 cell polarization. Th2 cells produce 
mainly IL-4, IL-13 and IL-5, and express the transcription factor GATA-3 (Fig. 
6). Their cell targets are eosinophils and basophils (Miossec P et al., N Engl J 
Med, 2009). Th2-type responses are important in allergic reactions, helminth 
infections, and anti-inflammatory actions (Abbas AK et al., Nature, 1996). Th 
cells that produce IL-17 but not IFN-γ or IL-4 were named Th17 cells (Park H et 
al., Nat Immunol, 2005). Despite the dependence of Th17 cells on IL-23, their 
initial development from naïve T cells requires transforming growth factor (TGF)-
β and IL-6 or IL-21 (Fig. 6), and this process is enhanced by TNF-α and IL-1β 
(Stockinger B and Veldhoen M, Curr Opin Immunol, 2007). IL-23 is required in 
the later stage of Th17 development for their terminal differentiation into mature 
effector cells (McGeachy MJ et al., Nat Immunol, 2009). Development of the 
Th17 lineage is directed by two transcription factors, RORγt and RORα (Ivanov II 
et al., Cell, 2006; Yang X et al., Immunity, 2008). Initial commitment to the Th17 
lineage is antagonized by Th1 and Th2 cytokines, and both IFN-γ and IL-4 
suppress Th17 differentiation (Harrington LE et al., Nat Immunol, 2005; Park H et 
al., Nat Immunol, 2005). Th17 cells express a range of pro-inflammatory 
mediators including IL-17A, IL-17F, IL-22, and IL-21 (Ghilardi N and Ouyang 
W, Semin Immunol, 2007). These cells constitute a distinct lineage of Th cells, 
with key role in protection against extracellular bacterial and fungal infections. 
While Th cell subsets are necessary for providing immunity against infectious 
pathogens, their aberrant response is to blame in several medical problems such as 
autoimmune diseases, allergies and malignancies. Therefore, a Th cell type could 
be either “good” or “bad” depending on the immunological context. Studies in 
humans as well as in animal models of MS suggest that Th1 and Th17 cells are 
mostly pathogenic, while Th2 and Treg cells are anti-inflammatory. 
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Figure 6. Different T helper cell subsets. Upon activation, naïve precursor T cell 
differentiates into effector T cell subsets, producing different cytokines and 
mediating distinct effector functions (Picture adapted from Wu RQ et al., Int J 
Oral Sci, 2014).  
 
Autoreactive Th1 and Th17 cells in multiple sclerosis and its animal model 
Th1 cells were thought originally to be the main pathogenic T cells in EAE and 
MS. It was postulated that during EAE, in the peripheral lymphoid organs, T 
precursor myelin-reactive T cells are induced to differentiate into myelin-reactive 
Th1 cells when an antigen that crossreacts with a myelin antigen is presented to a 
T cell by an APC in the context of IL-12 and co-stimulatory molecules. Th1 cells 
that react with myelin antigens, such as PLP, MBP and MOG, cross the BBB 
where the myelin antigens are represented to the T cell by APCs in the brain 
(microglia cells), and an inflammatory cascade is triggered with the release of 
inflammatory mediators that cause damage to the myelin sheath and ultimately the 
underlying axon. This conclusion was based partly on the observation that IFN-γ 
was detected in MS lesions (Traugott U and Lebon P, Ann Neurol, 1988) and in 
the CNS of EAE mice at the peak of disease and disappeared in CNS lesions 
during recovery (Olsson T, J Neuroimmunol, 1992; Issazadeh S et al., J Neurosci 
 25 
Res 1995). As described previously, the differentiation of Th1 cells is dependent 
on IL-12. IL-12 is a heterodimeric protein composed of p40 and p35 subunits 
(Gately MK et al., Annu Rev Immunol, 1998). Since p40 knockout (KO) mice or 
wild-type mice treated with antibodies to p40 are entirely resistant to EAE 
(Leonard JP et al., J Exp Med, 1995; Becher B et al., J Clin Invest, 2002), this 
further had supported the paradigm that Th1 cells were responsible for inducing 
the disease.  
The concept of Th1 driven organ-specific autoimmunity was challenged when it 
was found that mice deficient for p35, the second subunit of IL-12, were not 
protected from EAE but developed more severe disease (Becher B et al., J Clin 
Invest, 2002). IL-23 is a recent discovered cytokine that shares p40 subunit with 
IL-12 in combination with p19 subunit (Oppmann B et al., Immunity, 2000). 
Whereas IL-12p35 KO mice are more susceptible to EAE, IL-23p19 KO mice are 
absolutely protected from the disease (Cua DJ et al., Nature, 2003). It was also 
demonstrated that IL-23 could supports the differentiation of Th17 (Langrish CL 
et al., J Exp Med, 2005). Moreover, IL-17 was found highly expressed in tissue 
sites of many autoimmune diseases including MS lesions (Lock C et al., Nat Med, 
2002). High levels of IL-17 producing CD4+ T cells were detected also in the 
peripheral blood and in the cerebrospinal fluid of RRMS patients. Moreover, the 
onset of EAE was significantly delayed and the severity of disease was reduced in 
IL-17 -/- mice, even though the clinical incidence appeared similar compared with 
wild type animals (Komiyama et al. 2006). The cumulative data suggested an 
important role of IL-17 and Th17 cells in inducing tissue inflammation and 
autoimmunity, but their contribution in EAE pathogenesis is still poorly 
understood.  
Both Th1 and Th17 cells infiltrate the CNS during EAE but their relative 
proportions varied among different mouse strains (Langrish CL et al., J Exp Med 
2005; Korn T et al., Nat Med 2007). In C57Bl/6 mice, autoreactive Th1 cells 
predominate in the inflamed CNS at disease peak, whereas in SJL mice, Th17 
cells are more numerous (Langrish CL et al., J Exp Med, 2005; Korn T et al., Nat 
Med 2007). Immunization of mice with distinct MOG epitopes elicits T cell 
responses with a different Th1 to Th17 ratio, depending on the avidity of T cells 
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for their cognate antigen (Stromnes IM et al., Nat Med, 2008). These data suggest 
that the relative contribution of Th1 and Th17 responses in CNS inflammation 
might vary depending on the strain of mice and immunization strategy. 
Another important feature of EAE is that the pathology induced by Th1 and Th17 
cells is distinct. Th1-mediated CNS inflammation is characterized by infiltrating 
macrophages, whereas neutrophils predominated when Th17 cells are used to 
induce disease (Kroenke MA, J Exp Med, 2008). Moreover, Th1 and Th17 cells 
have a comparable capacity to induce EAE, although with different regional 
localization of CNS lesions and different clinical disease (Stromnes IM et al., Nat 
Med, 2008). Transfer of Th17 cells induces mainly brain inflammation in 
recipient mice, which developed atypical EAE, while transfer of Th1 cells leads to 
the development of classical EAE with only spinal cord (SC) inflammation. 
Interestingly, transfer of MOG-specific T cells containing different proportions of 
Th1 and Th17 cells directs the localization of CNS inflammation: a high 
Th17/Th1 cell ratio of CNS-infiltrating T cells, inflammation occurs in the brain 
parenchyma whereas in the presence of a lower Th17/ Th1 ratio inflammation is 
located in the SC (Stromnes IM et al., Nat Med, 2008). Studies in MS patients and 
normal human donors have provided evidence that Th1 and Th17 cells are active 
or expanded during diseases, but their contribution to pathology has, 
understandably, been more difficult to define, thus much of the focus in recent 
literature has been on the relative role of Th1 and Th17 in EAE and MS. 
Lymphocyte migration into the brain represents a critical event in the 
pathogenesis of MS and its animal model, EAE. MS and EAE pathogenesis is 
mediated by myelin-specific T cells, which are activated in the periphery and 
translocate into the CNS followed by permeabilization of the BBB (Furtado GC et 
al., J Immunol 2008; O’Connor RA, J Immunol, 2008). Among pro-inflammatory 
myelin-specific T cells, Th1 and Th17 cells are key players in the induction of 
brain autoimmunity, but the different molecular mechanisms controlling their 
dynamics from inflamed vessels to CNS parenchyma are not well understood. 
Upon entering the CNS, the T cells are reactivated by local and infiltrating 
activated APCs, which present MHC-II-associated peptides, resulting in 
subsequent inflammatory process and eventually in demyelination and axonal 
 27 
damage. In this process is very important how T cells move and interact with 
others immune cells, in fact the responses to potential antigen inside the CNS 
require long-range migration of cells, short-range communication and direct cell-
cell contact with APCs. Moreover, the communication between cells and their 
environment is of the significant importance since influence different processes as 
proliferation, survival and motility, as well as regulate effector functions. 
 
In vivo imaging techniques allow to study T leukocytes trafficking in the central 
nervous system 
Epifluorescence intravital microscopy (IVM) and multiphoton microscopy enable 
imaging of leukocyte trafficking in the CNS. Providing qualitative and 
quantitative data concerning the molecular mechanisms that control leukocyte 
migration, IVM technique is suitable for the understanding of leukocyte-
endothelial cells interactions, particularly slow rolling, tethering, arrest and 
adhesion strength in CNS vessels. This technique could also help to identify the 
role of selectins and integrins in the recruitment of different cell subsets and is 
ideal for the study of leukocyte trafficking during EAE. Particularly, a vertebral 
window over the pial vessels of the lumbar column at L1-L5 enables to follow T 
cell migration at the main site of inflammation of EAE (Fig. 7A, B, C, D). 
Multiphoton microscopy is more suited for studies on transmigration and motility 
mechanisms inside tissue parenchyma (Fig. 7E, F) (Zenaro E et al., Immunology 
and cell biology, 2013). 
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Figure 7. IVM and TPLM experimental settings. The main site of 
inflammation in MOG-induced EAE was exposed and laminectomy over L1-L5 
was carefully performed both in IVM and TPLM experiments (A). The 
preparation for IVM was placed under microscope on a water immersion 
objective with long focal distance (B). Pial vessels of the exposed SC were 
visualized at IVM by using fluorescent dextrans (C). Digital videotapes at IVM of 
the interacted cells with the inflamed endothelium (D). The preparation for TPLM 
fitted on a customized microscope stage was placed under microscope without 
coverglass to permit the direct immersion of the objective (E). Pial vessels and 
exogenous infiltrated T cells in the SC parenchyma were visualized at TPLM by 
using fluorescent dies (F) (Picture adapted from Zenaro E et al., Immunol. Cell 
Biol., 2013). 
 
Two photon laser microscopy technique: principles and applications in the 
study of the dynamic nature of immune cells 
Two-photon laser microscopy (TPLM) allows visualizing immune 
processes within the living animal by providing dynamic views of sub-cellular 
structures and cells in a tissue context in vivo. TPLM is an ideal tool for long-term 
intravital imaging because of its low phototoxicity, superior penetration depth and 
high resolution (Matz MV et al., Nat Biotech, 1999). The difference between two-
photon microscopy and one-photon microscopy, such as confocal and fluorescent 
microscopes, involves the excitation process. During conventional (one-photon) 
excitation a fluorescent molecule absorbs a photon with a specified energy. In 
contrast, during two-photon excitation, a fluorescent molecule is excited 
simultaneously by two photons that sum up their energy to activate it. After non-
radiative relaxation, a fluorescent molecule emits fluorescence, which is common 
capture from the bloodstream, whereas integrin LFA-1 is involved in
firm adhesion and leukocyte extravasation.49,50
Previous IVM studies in spinal cord pial vessels have used a
vertebral window over C1–C7, which are not severely affected by
EAE.51 We have recently developed a method allowing the
visualization of pial vessels in the lumbar column over L1–L5, which
are preferentially targeted by inflammation mechanisms during EAE.
Mice are deeply anesthetized using intraperitoneal ketamine/xylazine
and then immobilized on a stage under a dissection microscope. After
removing the skin, a midline dorsal incision is used to expose the
lumbar column over L1–L5. Muscles are dissected from vertebral
bones on both sides and a laminectomy is carried out by gentle bone
scraping to expose the spinal cord (Figure 2a). This maintains an
intact dura mater layer to protect the spinal cord. After surgery, the
spinal cord is protected from dehydration and environmental oxygen
by adding drops of artificial CSF and sealing with a glass coverslip. A
round chamber is attached to the coverslip and filled with water as
described above, to allow the immersion of the microscope objective
(Figure 2b).
The anatomy of the spinal cord white matter microvasculature is
characterized by a large dorsal median vein, which receives veins from
the dorsal white matter columns and drains blood caudally. The
capillary network is characterized by multiple vessel loops as shown in
Figure 2c. Although the blood flow in the major collecting venule
shows respiratory-dependent flow motion, blood in the capillary
network and post-capillary venules is characterized by physiological
hemodynamic parameters.49
VIDEO ACQUISITION AND ANALYSIS OF LEUKOCYTE
INTERACTIONS
Video images are digitalized and stored using a recorder/converter,
allowing data analysis using QuickTime Player or ImageJ software Q2.
Vessel diameters (D), hemodynamic parameters and rolling velocities
are can be determined using computer-assisted image analysis systems
such as NIH Q3Image software. The velocities of 20 consecutive freely
flowing cells per venule are determined, allowing the calculation of
the velocity of the fastest cell in each venule (Vmax) and the mean
blood flow velocity (Vmean) using the formula Vmean¼Vmax/(2"e2)
where e is the ratio of cell diameter to vessel diameter. The wall shear
rate (WSR), which provides an indication of the force on the vessel
wall caused by blood flow, is calculated as follows: WSR¼ 8#Vmean/
D (s"1). The WSS acting on rolling cells can then be estimated as
follows: WSS¼WSR# 0.025 (dyne cm"2) assuming a blood viscosity
of 0.025Poise.52 WSR can influence leukocyte–endothelium interac-
tions under inflammatory conditions, so the above calculations help
to ensure that the impact of environmental fluctuations is not
included in the final result.53
Leukocyte–endothelial cell interactions are usually sampled in
venules ranging from 20–100mm in diameter. Leukocytes are con-
sidered to be rolling if they travel at velocities below Vcrit which is
determined as follows: Vcrit¼Vmean# e# (2"e).22,25 Typically,
leukocytes are considered to be in adhesion if they are in firm
arrest for at least 10–30 s. Cells either rolling or in firm arrest are
determined as the percentage of cells that rolled or firmly arrested
within a given venule based on the total number of cells that entered
Figure 2 Surgery and epifluorescence IVM imaging of spinal cord venules. A heparinized catheter was inserted into the tail vein of anesthetized mice, to
inject fluorescent leukocytes. After skin removal, muscles were dissected from the sides of the vertebral bone nd a midline dor al incision exposed the
lumbar column over vertebrae L1–L5. Laminectomy was performed to expose the spinal cord. (a) Stereomicroscopic view of exposed spinal cord vessels.
(b) Exposed spinal cord covered with artificial CSF following surgery. A coverslip is applied on the exposed area. A water immersion objective is used to
visualize spinal cord vessels through the intact dura. (c) IVM images of exposed spinal cord microcirculation, showing small-diameter pial vessels draining
blood flow into the central large collecting venule (dorsal median vein). Spinal cord vessels were visualized by the injection of fluorescent dextran (scale
bar¼100mm). (d) Fluorescence-labeled TH1 cells injected at the disease peak in MOG35–55-immunized EAE mice. Labeled cells can be injected into the
tail vein or through a catheter inserted into the carotid artery towards the aortic arch. Cells are revealed as bright intravascular dots, adhering to
the inflamed spinal cord endothelium. Note that cells interact with inflamed vessels both in the small-diameter pial venules and in the central large
collecting venule (scale bar¼100mm).
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capture from the bloodstream, whereas integrin LFA-1 is involved in
firm adhesion and leukocyte extravasation.49,50
Previous IVM studies in spinal cord pial vessels have used a
vertebral window over C1–C7, which are not severely affected by
EAE.51 We have recently developed a method allowing the
visualization of pial vessels in the lumbar column over L1–L5, which
are preferentially targeted by inflammation mechanisms during EAE.
Mice are deeply anesthetized using intraperitoneal ketamine/xylazine
and then immobilized on a stage under a dissection microscope. After
removing the skin, a midline dorsal incision is used to expose the
lumbar column over L1–L5. Muscles are dissected from vertebral
bones on both sides and a laminectomy is carried out by gentle bone
scraping to expose the spinal cord (Figure 2a). This maintains an
intact dura mater layer to protect the spinal cord. After surgery, the
spinal cord is protected from dehydration and environmental oxygen
by adding drops of artificial CSF and sealing with a glass coverslip. A
round chamber is attached to the coverslip and filled with water as
described above, to allow the immersion of the microscope objective
(Figure 2b).
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blood flow velocity (Vmean) using the formula Vmean¼Vmax/(2"e2)
where e is the ratio of cell diameter to vessel diameter. The wall shear
rate (WSR), which provides an indication of the force on the vessel
wall caused by blood flow, is calculated as follows: WSR¼ 8#Vmean/
D (s"1). The WSS acting on rolling cells can then be estimated as
follows: WSS¼WSR# 0.025 (dyne cm"2) assuming a blood viscosity
of 0.025Poise.52 WSR can influence leukocyte–endothelium interac-
tions under inflammatory conditions, so the above calculations help
to ensure that the impact of environmental fluctuations is not
included in the final result.53
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Figure 2 Surgery and epifluorescence IVM imaging of spinal cord venules. A heparinized catheter was inserted into the tail vein of anesthetized mice, to
inject fluorescent leukocytes. After skin removal, muscles were dissected from the sides of the vertebral bone and a midline dorsal incision exposed the
lumbar column over vertebrae L1–L5. Laminecto y was performed to expose the spinal cord. (a) Stereomicroscopic view of exposed spinal cord vessels.
(b) Exposed spinal cord covered with artificial CSF following surgery. A coverslip is applied on the exposed area. A water immersion objective is used to
visualize spinal cord vessels through the intact dura. (c) IVM images of exposed spinal cord microcirculation, showing small-diameter pial vessels draining
blood flow into the central large collecting venule (dorsal median vein). Spinal cord vessels were visualized by the injection of fluorescent dextran (scale
bar¼100mm). (d) Fluorescence-labeled TH1 cells injected at the disease peak in MOG35–55-immunized EAE mice. Labeled cells can be injected into the
tail vein or through a catheter inserted into the carotid artery towards the aortic arch. Cells are revealed as bright intravascular dots, adh ring to
the inflamed spinal cord endothelium. Note that cells interact with inflamed vessels both in the small-diameter pial venules and in the central large
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capture from the bloodstream, whereas integrin LFA-1 is involved in
firm adhesion and leukocyte extravasation.49,50
Previous IVM studies in spinal cord p al vessels have used a
vertebral window over C1–C7, which are not severely affected by
EAE.51 We have recently developed a method allowing the
visualization of pial vessels in the lumbar column over L1–L5, which
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in both conventional and two-photon excitation (Fig. 8A). In this situation, two 
photons merge their energy and excite a single fluorochrome. As two-photons 
excite one fluorochrome, each photon used in one-photon microscopy harbors half 
of the energy used in conventional microscopy. Therefore, the wavelength used in 
two-photon microscope is twice as long as in one-photon microscopy. 
Specialized lasers had to be developed for practical realization of TPLM. Indeed, 
the most widely used light sources are characterized by high repetition rate, 
ultrafast pulsed lasers, such as titanium-sapphire and Nd:YLF lasers (So P TC, 
Encyclopedia of life sciences, 2002). Generated photons are then focused by the 
objective lens of the microscope, leading to their maximal accumulation at the 
focal point (Fig. 8B).  
 
 
 
Figure 8. Comparison between conventional single photon excitation (SPE) 
versus two-photon excitation (TPE).  
During conventional excitation, a photon activates a fluorescence molecule (blue 
arrow), whereas during two-photon excitation, two photons can sum up their 
energy to activate a fluorescence molecule (red arrows). After nonradiative 
relaxation (green arrow), a fluorescence molecule emits fluorescence, which is 
common in both conventional and two-photon excitation (A). Conventional laser 
can excite a fluorescence molecule on its way causing an emitted cone of 
fluorescent light within the sample. In TPLM, fluorescent molecules can be 
activated only at the focus plane leading to less phototoxicity and less 
photobleaching (B) (Picture adapted from Bennewitz MF et al., Intravital, 2014). 
 
Since the two-photon effect occurs only at a focal point, there is no out-of-focus 
signal to be rejected. This explains why a two-photon microscope does not need a 
 30 
pinhole, while confocal microscopy requires it for removing the signal generated 
from outside the focal plane. TPLM allows studying the behavior of cells, in 
particular the immune cells, their dynamics, morphology, motility and signaling 
processes, while minimizing perturbation of the system under study.  
The study of cell migration needs to consider the fact that cells migrate in a 
densely packed extracellular matrix environment, surrounded by interstitial cells, 
other leukocytes or resident neural cells, as well as fixed tissue elements such as 
blood vessels along with a dynamic context of immunoregulatory mediators that 
might be diffusing freely or are immobilized to the underlying stroma (Sumen C 
et al., Immunity, 2004). Particularly, leukocyte migration into the tissues depends 
on the composition and architecture of matrix protein cross-interactions. The 
matrix composition controls cell adhesion and migration, and its sensitivity to 
proteolytic enzymes will determine the ability of the cell to remodel the matrix 
and migrate through it. 
TPLM has revealed the dynamic nature of immune cells within living lymphoid 
and target organs, in particular this technology has elucidated the dynamics of the 
autoreactive effector T cells in the course of EAE. Recent data have shown that 
myelin-specific T cells injected in an adoptive transfer model of rat EAE display a 
motility behavior suggesting that CNS cells present antigens and activate T cells 
inside SC parenchyma (Kawakami N et al., J. Exp. Med, 2005; Odoardi F et al., 
Proc. Natl. Acad. Sci., 2007). In fact, Bartholomäus and colleagues have recently 
demonstrated that rat T cells reactivate in the subarachnoid space (SAS) in the 
presence of leptomeningeal macrophages and that the efficiency of the 
reactivation in the presence of antigen is mandatory for subsequent invasion in 
CNS parenchyma of Lewis rat (Bartholomäus I et al., Nature 2009). However, 
and the molecular mechanisms implicated in the motility behavior of T cells 
inside CNS parenchyma and the interactions with neural cells in common mouse 
EAE models remain unknown. Moreover, the molecular mechanisms controlling 
Th1 and Th17 cells trafficking inside CNS parenchyma during neurological 
diseases is largely unknown. 
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Materials and Methods 
 
Mice 
8-10 weeks of age C57BL/6 female mice were used to active EAE induction. 2D2 
TCR transgenic mice were used to Th1 and Th17 cells production. These mice 
used in this study were with C57BL/6 genetic background. All animals were 
housed and used in according to the current European Community rules.  
 
Production MOG35-55 specific Th1 and Th17 cells 
We used 2D2 TCR transgenic T cells that recognize MOG35-55 peptide (Bettelli 
E et al., J Exp Med, 2003) to obtain sufficient numbers of Th1 and Th17 cells. We 
used a modified protocol by Domingues and colleagues, which the obtainment of 
large numbers of Th1 and Th17 cells free of contaminating IL-17 and IFN-γ 
producing cells in Th1 and Th17 polarizations, respectively (Domingues HS et al., 
PLoS One, 2010). 2D2 TCR transgenic mice were sacrificed and spleen cells were 
isolated. 20 x 106 2D2 total erythrocyte-lysed spleen cells per well were cultured 
for 7 days in the presence of 20 µg/ml antigenic peptide MOG (MOG35-55) in 
RPMI 1640 supplemented with 100 mM Na pyruvate, 200 mM in 0,85% NaCl 
solution ultraglutamine 1, 10000 U/ml penicillin, 10000 U/ml streptomycin and 
10% fetal calf serum (FCS). For Th1 and Th17 polarization the following 
cytokines and antibodies were further added in the culture. Th1: IL-12 (1 ng/ml), 
anti-IL-4 (10 µg/ml). Th17: TGF-β (5 ng/ml), IL-6 (20 ng/ml), IL-23 (2 ng/ml), 
anti-IL-4 (10 µg/ml), anti-IFN-γ (10 µg/ml). Th1 cells were supplemented with 
IL-2 (20 U/ml) and Th17 cells with IL-7 (10 ng/ml) at day 4 of culture. After 72 
hours, MOG-specific Th1 and Th17 cells were isolated by Ficoll-gradient 
centrifugation. MOG-specific Th1 and Th17 cells (approximately 30 x 106 
cell/plate) were re-stimulated in the presence of irradiated splenic APCs (120 x 
106 cell/plate) for 3 days with a proportion of 1:4. Then, cytokines and MOG were 
added in the culture as described previously. After, activated MOG-specific Th1 
and Th17 cells were isolated by Ficoll-gradient centrifugation and IL-2 (20 U/ml) 
and IL-7 (10 ng/ml) was added, respectively. 
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Detection of intracellular and extracellular cytokines 
For intracellular cytokines staining cells were stimulated for 4 hours with Phorbol 
12-myristate 13- acetate (PMA) (50 ng/ml), ionomycin (1 µg/ml) and brefeldin A 
(10 µg/ml). Permeabilized cells were labeled with FITC-conjugated rat anti-
mouse IFN-γ and PE-conjugated rat anti-mouse IL-17. As control, cells were 
stimulated with the same conditions, but without brefeldin A. 
For extracellular staining, the following rat anti-mouse monoclonal antibodies 
were used: anti-α4 (clone PS/2), anti-CD44 (clone MJ64), anti-L-sel (clone MEL-
14), anti-LFA-1 (clone TIB-213), anti-PSGL-1 (clone 2PH1), anti-α4β7 (clone 
DATK-32). Samples were collected and analyzed by fluorescence-activated cell 
sorting technology (FACS). 
 
Active EAE induction 
C57BL/6 mice were immunized with 150 µg/mouse of MOG35-55 peptide in 200 
µl/mouse of emulsion consisting of equal volumes of Dulbecco’s Phosphate 
Buffered Saline (PBS) and CFA, supplemented with 1 mg/mouse of 
Mycobacterium tubercolosis (strain H37Ra). CFA contains heat-killed 
Mycobacterium tubercolosis that stimulates the innate immune system. 
Immunization was made sub-cutaneously in the flank (100 µl/flank). Mice also 
received 40 ng of pertussis toxin (PTX) with intravenous injection at the time of 
immunization (day 0) and 48 hours later (day +2). Toxicity may vary by lot of 
toxin depends on its Adenylate Cyclase activity. The optimum dosage of each lot 
of PTX was determined based on EAE clinical symptoms appearance and disease 
severity. Mice were checked for clinical symptoms daily and signs of EAE were 
translated into clinical score as follows: 0= no disease, 1= tail weakness; 2= 
paraparesis; 3= paraplegia; 4= paraplegia with forelimb weakness or paralysis; 5= 
moribund or dead animals. 
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Epifluorescence intravital microscopy 
IVM: experimental procedures 
Lymphocytes were labeled with either green CMFDA (5-chloromethylfluorescein 
diacetate) (Molecular probes) or orange CMTMR (5-(and-6)-
(((chloromethyl)benzoyl)amino)tetramethylrhodamine). Mouse was anesthetized 
with an intraperitoneal (i.p.) injection of ketamine (100 mg/kg body 
weight)/xylazine (15 mg/kg) and prepared for the SC exposure. The back of the 
animal was shaved and a midline dorsal incision of the skin was made to expose 
the lumbar column, the main site of inflammation. Skin was retracted and pulled 
to the side with small retractor clamps on either side to maintain the spine 
exposed. The paravertebral muscles were carefully incised and laminectomy over 
L1-L5, the main site of inflammation in MOG-induced EAE, to expose the SC. 
This procedure allowed us to leave an intact dura to protect the SC. Bleeding was 
controlled by making softly pressure on the area with gel foam or by using small 
vessel cauterizer. (Davalos D et al., J Neurosci Methods, 2008; advances in 
intravital microscopy book) (Fig. 7A). At the end of microsurgery, a 24mm x 
24mm coverslip was applied on the exposed SC. A round camera with 11mm 
internal diameter was attached on the coverslip and filled with water (Fig. 7B).  
 
IVM: imaging acquisition  
The preparation was placed on an Olympus BX50WI microscope and a water 
immersion objective with long focal distance (focal distance 3.3 mm, NA 0.5 ∞) 
was used. Blood vessels were visualized by using fluorescent dextrans. 2 x 107 
fluorescent labeled cells/condition were slowly injected into the tail vein. The 
images were visualized by using a silicon-intensified target videocamera (VE-
1000 SIT) and a Sony SSM-125CE monitor and recorded employing a digital 
VCR (Fig. 7C, D). 
 
IVM: integrins blockade experiments 
In order to identify a potential role of integrins in the molecular mechanisms 
responsible for Th1 and Th17 cell trafficking on the inflamed pial vessels of the 
SC, labeled cells were treated with blocking monoclonal antibodies anti-LFA-1 
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integrin (clone TIB-213), anti-a integrin (clone PS/2) and anti a4b7 (clone 
DATK32). Cells were incubated at 37° C for 10 minutes with a concentration of 
blocking mAbs at 100 µg/ml. Then cells were intravenously administrated in 
200 µl of PBS together with additional 100 µg/ml mAb. 
 
IVM: image analysis 
Video analysis was performed by playback of digital videotapes. Vessel diameter 
(D), hemodynamic parameters and the velocities of rolling were determined by 
using a PC based system (74). The velocities of ³ 20 consecutive freely flowing 
cells/venule were calculated, and from the velocity of the fastest cell in each 
venule (Vfast), we calculated the mean blood flow velocities (Vm): Vm=Vfast/(2-e2). 
The wall shear rate (WSR) was calculated from WSR=8xVm/D (s-1), and the wall 
shear stress (WSS) acting on rolling cells was approximated by WSR x 0.025 
(dyn/cm2), assuming a blood viscosity of 0.025 Poise. Lymphocytes that remained 
stationary on venular wall for ³ 30 s were considered adherent. At least 100 
consecutive cells/venule were examined. Rolling and firm arrest fractions were 
determined as the percentage of cells that rolled or firmly arrested within a given 
venule in the total number of cells that entered that venule during the same period.  
 
IVM: statistics  
Statistics on the comparison of rolling and adhesion events between Th1 and 
Th17 during the different phases of the disease were calculated using Mann-
Whitney test, which is a non parametric test with confidence interval of 95%. The 
reduction of rolling and adhesion events after antibody treatment was evaluated as 
percentage compared to control cells (100% of interactions). Statistics were 
calculated by using a one sample t test to the hypothetical control value fixed at 
100. It’s a two tailed test. A confidence interval of 95% was assumed. Data are 
expressed in mean ± standard error mean (SEM).  
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Two photon laser microscopy 
TPLM: surgical procedures 
Th1 or Th17 cells were labeled for 45 min at 37°C with 40 mM 7-amino-4-
chloromethylcoumarin (CMAC) or carboxyfluorescein succinimidyl ester 
(CFSE). 2 × 107 of Th1 or Th17 cells were transferred intravenously (i.v.) 
injection in a C57BL/6 recipient mouse at different disease phases as shown. 48 
hours after mouse was anesthetized with an intraperitoneal (i.p.) injection of 
ketamine (100 mg/kg body weight)/xylazine (15 mg/kg) and prepared for the SC 
exposure. A midline dorsal incision was made to expose the lumbar column over 
L1-L5, as described in intravital microscopy surgical procedures. Muscles were 
dissected from the sides of the vertebral bone and a small retraction of the 
paravertebral muscles allowed the insertion of the fine tips of the clamping of a 
spinal column stabilization device. We used an adapted method by Davalos et al. 
fitted on a customized microscope stage in the mechanical facility at the 
University of Verona. This method presents excellent stability by combining a 
customized spinal stabilization device (Narishige STS-A Compact Spinal Cord 
Clamps and Narishige MA-6N head holding adaptor on a steel base that will be 
adapted to fit on the microscope's stage) with a method of deep anesthesia 
minimizing respiratory-induced movements. This method allows optimal SC 
immobilization and eliminates the impact of respiratory movements for two 
photon microscopy studies (Davalos D et al., J Neurosci Methods, 2008). Few 
drops of artificial cerebrospinal fluid (CSF) were added on SC without cover glass 
to permit the direct immersion of the microscope objective (Fig. 7E). Blood 
vessels were stained by i.v. injection of fluorescent Qtracker quantum dots 655 
(Qdots-655) immediately before imaging (Fig. 7F). 
 
TPLM: integrin blockade experiments 
In order to identify a potential role of integrins in the adhesion mechanisms 
responsible for Th1 and Th17 cell motility behavior into the SC parenchyma, 
blocking monoclonal antibodies anti-LFA-1 integrin (clone TIB-213) and anti-a4 
integrin (clone PS/2) were locally administrated. Antibodies (100 µg/ml) were 
administered in 200 µl of artificial CSF on the exposed SC and incubated for 30-
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60 min before the imaging to permit adequate local tissue diffusion (Kim JV et 
al., Nature 2009). 
 
TPLM: imaging acquisition 
The mouse was positioned on stabilizing device and maintained at 37°C using a 
thermostatic blanket system and placed on a customized upright Leica TCS SP5 
AOBS confocal-multiphoton system. CMAC- or CFSE-labeled Th1 and Th17 
cells and Qdots-655-labeled vessels were excited with a mode-locked Ti:Sapphire 
Chameleon Ultra II laser (Coherent Inc) and visualized with an Olympus 
XLUMPlanFI 20× objective (water immersed, numerical aperture, 0.95). For 
imaging, we used simultaneous laser excitation at 750-800 nm. Fluorescence 
emission from the three different fluorescent dyes was separated passing through 
panchromatic electronic barrier filters and detected as red (560–650 nm), green 
(490–560 nm), and blue (400-500 nm) signal.  
Stacks of images were acquired using Leica acquisition software. To create time-
lapse sequences, we scanned volumes of tissue in which each plane consists of an 
image of 100 × 120 µm (x and y = 2 pixel/µm). Z-stacks were acquired by taking 
21 sequential steps at 2.5 µm spacing at 27-35-s intervals for up to 30 min. To 
increase signal contrast, we averaged 2 video frames for each z-slice. 
Multidimensional rendering was performed with Imaris (Bitplane). 
 
TPLM: data analysis 
Sequences of image stacks (Fig.9A, B) were transformed into volume-rendered 
three-dimensional movies and cell movement analysis was obtained using Imaris 
software (Fig. 9C, E). Three-dimensional spatial position of each cell was 
detected based on centroid fluorescence intensity. Tracks for each cell consist of 
serial sets of xyz coordinates of single cell centroid (Fig. 9F). Once the cell tracks 
were created they were exported from Imaris to calculate several parameters that 
can be used to describe the migration behavior of cells quantitatively (Fig. 9G). 
Cells were tracked over time manually and tracks greater than 3 min (≥12 time 
points) were included in the analysis. Intra-tissue tracking of robust number of 
cells was performed: i) fields with at least 20 fluorescent leukocytes were 
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considered for analysis; ii) a mean of 4 fields/mouse were examined; iii) at least 
100 manually tracked cells were considered for each experimental condition. 
The following parameters were calculated (Fig. 10): cell velocity was analyzed 
either as instantaneous velocity (Fig. 10D) or track velocity, the former providing 
a basic parameter derived from the displacement of the cell centroid between 
adjacent time periods whereas the latter is obtained from the median or mean 
instantaneous velocity computed from all time intervals throughout a track. The 
displacement of a cell moving with a constant velocity from an initial position but 
randomly changing direction is on average linearly proportional to the square root 
of the elapsed time (Fig. 10C, E). The most accurate current method to detect 
migration patterns is the mean displacement plot, in which the average 
displacement of a population of cells over specific time intervals is plotted against 
the square root of time. The slope of the resulting curve can be used to determine 
the motility coefficient of a cell population (Fig. 10E) and measures the volume an 
average cell scans per unit time. The arrest coefficient is another useful parameter, 
representing the proportion of time during tracking in which a cell does not move 
(threshold <2 µm/min). The arrest coefficient was calculated from cell tracks, so 
the reported value represents a percentage of cells in the entire population. For 
example, the arrest coefficient is generally high when T cells are in stable contact 
with other cells or swarm in a chemoattracting microenvironment. The 
meandering index was also calculated, based on the ratio of displacement from 
origin by track length, to provide another index of the directness of cell 
movement. A meandering index of 0.7-1 generally indicates that cell migration 
has a strong directional bias (Fig. 10F) (Zenaro E et al., Immunol Cell Biol, 2013). 
 
TPLM: statistics 
 Statistics were calculated using non parametric Mann-Whitney test with 
confidence interval of 95%. Data on Th1 and Th17 motility behavior during the 
different phases of EAE are expressed in mean ± standard deviation (SD). 
Compared data between Th1 and Th17 cells before and after blocking antibody 
treatments were expressed in mean ± standard error mean (SEM). In the plot of 
displacement and chemotactic index we applied linear regression and compared 
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slopes. 
 
EAE induction and antibody treatment 
8 to 10 weeks old C57Bl/6J females were immunized sub-cutaneously in the 
flanks and in the tail base with 150 µg of MOG35-55 peptide in 200 µl emulsion 
consisting of equal volumes of PBS and CFA (Difco Laboratories), supplemented 
with 1 mg/mouse of Mycobacterium tuberculosis (strain H37Ra; Difco 
Laboratories). Mice received 40 ng of pertussis toxin (Alexis Biochemicals) 
intravenously (i.v.) at the time of immunization and 48 hours later. Clinical scores 
were recorder daily as previously described. For therapeutic anti-LFA-1 and anti-
a4b7 treatment, mice were injected intrathecally with two intracisternal injections 
of 10 µl containing 50 µg of anti-LFA-1 antibody (M17/4 clone) and anti-a4b7 
(DATK32 clone) or control anti-Ras monoclonal antibody. Mice were injected the 
day after disease onset, 4 and 3 days later for anti-LFA-1 and anti-a4b7 treatment, 
respectively. For intracisternal injection each mouse was anesthetized with a 
ketamine-xilazine solution and the atlanto-occipital membrane was punctured 
with Hamilton syringe by a 27-gauge needle and the antibody solution was 
administered as previously describe (Furlan R et al., Methods Mol Biol, 2003). 
Clinical scores data were expressed in mean ± standard error mean (SEM). 
Statistics were calculated using non parametric Mann-Whitney test.  
 
Neuropathology 
EAE mice were sacrificed 3 days after the first intrathecal antibody injection and 
SCs were collected and frozen. 20 µm sections were obtained for histological 
examination by hematoxylin/eosin and luxol fast blue staining for the presence of 
inflammatory infiltrates and demyelination, respectively (Butti E et al., Gene 
Ther, 2008). Microglia was stained using an anti–mouse ionized calcium binding 
adaptor molecule-1 antibody (Iba-1) (Wako) as described previously (Zenaro E et 
al., Nat Med, 2015).  
Total cord area, posterior column area, gray matter area and lateral, anterolateral, 
anterior column area were traced. Areas (mm2) were manually outlined and 
calculated by an automated quantification system using ImageJ v1.49 software 
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(NIH). Results from quantification of neuropathological findings on an average of 
4-6 cross sections of SC per mouse taken at different levels of lumbar and thoracic 
regions are expressed as percentage on white matter area or total area respectively 
(McGavern DB et al., Neurosci Res, 1999). The numerical density of Iba-1+ 
immunoreactive microglia was quantified by determination of the total number of 
positive elements and reported as number of positive elements per mm2. 
Activation state of microglia was determined quantifying the area covered by the 
cell soma and expressed as percentage of Iba-1+ cells on total area as previously 
reported by Zenaro E and coworkers. A lowering microgliosis results in terms of 
reduction of the area covered by cell soma of Iba-1+ cells (Zenaro E et al., Nat 
Med, 2015). The activated microglia shows a globoid, thus smaller morphology. 
However, the portion of area covered by these globoid cells, results more 
extensive than the area covered by microglial ramified cells. This is probably due 
to a reduction in the complexity of cells but in an increasing of cell soma 
dimensions. A support of that, cell body size parameter was found positive 
correlated with microglial activation. Indeed, the cell body to cell size ratio 
emerged as novel method to evaluate the activation state of microglia cells 
(Hovens IB et al., Neuroimmunol Neuroinflammation, 2014). Accordingly, an 
other parameter used, in particular with fluorescent microglia, is the domain 
volume (µm3) that results significantly higher in the activated microglia compared 
to the control cells (Plog BA et al., J Neurosci Methods, 2015).  
All images were captured using a Leica microscopy DM6000B and the Leica 
Application Suite software. All data were expressed in mean ± standard error 
mean (SEM). Statistics were calculated using non parametric Mann-Whitney test. 
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Figure 9. Acquisition of the in vivo cell motility by TPLM: steps 
demonstration.  A pulsed bundle of infrared (IR) laser light is raster scanned via 
a microscope objective with high numerical aperture into a thick specimen by fast, 
synchronized movement of a pair of mirrors. Fluorescent signals are generated by 
the multiphoton excitation in a ~1µm deep section at the focal plane (A). The 
specimen stacks of optical sections are serially reacquired at defined time 
intervals (in this example, 15 s are required to acquire one z stack composed of six 
optical sections) (B). Each z stack is rendered as a three-dimensional volume (C), 
and two-dimensional projections of image stacks are exported as movie files for 
the off-line analysis (D). Determination of cell centroids to represent cell position 
allows automated or manual tracking of migration paths (E). Tracks consisting of 
serial sets of xyz coordinates of single cell centroids are exported as numerical 
databases, and are used to compute parameters of cell motility with specialized 
software for 2D or 3D cell tracking (G) (Picture adapted from Sumen C et al., 
Immunity, 2004). 
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Figure 10. Analysis of the in vivo cell motility by TPLM: basics of motility 
parameters. Visualization of the 3D locations of fluorescently labeled cells at a 
single time point with tracks of three cells as demonstration (A). Plot 
representation of 2D tracks of several cells, rendering after normalizing their 
starting coordinates to the origin (B). A track of a cell at five successive time 
points, t1, t2, etc is showed. Instantaneous velocities are calculated from the net 
distance d traveled during each time interval Δt, and the turn angle θ is the angle 
through which the cell turns between time steps. The displacement D is the 
straight-line distance of the cell from its origin at any given time. Path length is 
given by the sum of d1, d2, d3, etc. Persistence time (or length) is the time for 
which a cell continues to move without turning appreciably, as is illustrated for 
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time points t2–t4 (C). The instantaneous velocity of T cells sways in a 
characteristic manner over time, accompanied by changes in shape index (long 
axis/short axis) as the cell elongates while moving fast (D). If cell motility follows 
a random walk the plot of mean displacement from origin of multiple cells is 
expected to follow a straight line when plotted as a function of square root of 
time. The slope of this line can be used to derive a motility coefficient M, 
analogous to the diffusion coefficient for Brownian motion. Deviations from a 
straight-line relationship may be indicative of directed migration (upward 
curvature) or migration constrained by physical or biological barriers (plateau) 
(E). The measure defined as the ratio between displacement and path length from 
origin, namely chemotactic index, remains constant with a value of unity for 
linear-directed motion but decreases progressively with time if cells follow a 
random walk (F) (Picture adapted from Cahalan MD and Parker I, Ann Rev 
Immunol, 2008).  
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Results 
Characterization of Th1 and Th17 cytokine production and their adhesion 
molecule expression 
By using flow cytometry analysis, we first evaluated the purity of Th1 and Th17 
cells preparation in term of cytokines production. We obtained bulk numbers of 
Th1 and Th17 cells free of contaminating IL-17 and IFN-g producing cells in Th1 
and Th17 cells, respectively. In Th1 cultures we achieved more than 50% of T 
cells that produced IFN-g and in Th17 cultures 40% of cells produced IL-17 (Fig. 
11). We next investigated the following adhesion molecule expression on Th1 and 
Th17 cells: a4 integrin chain, a4b7 integrin, LFA-1, CD44, L-selectin and PSGL-
1 (Fig. 12). Th17 cells showed a significantly lower percentage of expression for 
L-selectin when compared to Th1 cells suggesting a higher state of activation. 
a4b7 integrin expression was higher on Th17 cells compared to Th1 cells (Fig. 
12A). Interestingly the mean intensity fluorescence (MIF) of LFA-1 was 
statistically higher on Th1 cells (Fig. 12B). These data show a different integrin 
expression pattern in Th1 and Th17 cells, suggesting they may use different 
mechanisms during their migration and motility in the inflamed tissues. 
 
Epifluorescence intravital microscopy results 
Th1 and Th17 cells differently interact with inflamed CNS endothelium during 
EAE  
We analyzed the intravascular interactions of fluorescently labeled exogenous 
Th1 and Th17 at different phases of EAE, in particular at the preclinical phase (7 
dpi;), disease onset (11-14 dpi) and chronic phase (22-25 dpi; considered as 5 
days after clinical course stabilization). Autoreactive Th1 and Th17 cells were 
intravenously injected immediately before imaging. We first collected 
morphological data on the vessel diameters during the different phases of the 
disease. The morphological results showed a significant enlargement of the pial 
vessels of the SC at disease peak in comparison to the other phases analyzed (Fig. 
13, Table I). Results among the hemodynamic parameters analysis showed a 
great reduction in particular on the wall shear stress (WSS) at the onset of EAE 
compared to the other phases (Table I). In order to investigate the migration of 
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Th1 and Th17 cells in the CNS, we performed IVM experiments at different time 
points after EAE induction. In particular, we investigated Th1 and Th17 cell 
adhesion during the preclinical phase, disease onset and chronic phase. At the 
preclinical phase of the disease Th1 cells showed higher capacity to roll on vessel 
endothelium (26.5% versus 19.4%, *P=0.0172) and perform firm arrest in pial 
venules (4.4% versus 1.4%, **P=0.0026) when compared to Th17 cells. 
However, Th17 cells appeared more adhesive when compared to Th1 cells 
presenting higher capacity to roll (30.8% vs 21.0% respectively, *P=0.0412) and 
adhere (3.8% vs 2.2% respectively, *P=0.0419) in pial SC vessels during the EAE 
onset. IVM experiments performed during the chronic phase showed that Th1 and 
Th17 cells displayed a pair capacity to firm arrest in the pial venules (2.3% vs 2.8 
% respectively, P=0.3705) with a major tendency for Th1 cells to roll when 
compared to Th17 (25.5% vs 20.0% respectively, *P=0.0131) (Fig. 14, Table II).  
Basal frequency of T cell rolling and adhesion after transfer in naïve mice resulted 
from a previous work published by our laboratory’s group shown that non 
activated cerebral endothelium does not support lymphocyte interactions both of 
resting cells freshly isolated from peripheral lymphonodes and autoreactive 
encephalitogenic T cells (Piccio L, J Immunol, 2002). 
 
LFA-1 controls Th1 but not Th17 cell adhesion in inflamed CNS vessels  
We next investigated the role of LFA-1 in Th1 and Th17 cell trafficking in the 
CNS during EAE (Fig. 15). For this purpose, we pretreated T cells with blocking 
anti-LFA-1 antibody (clone TIB213). LFA-1 blockade in the preclinical phase of 
disease reduced Th1 cell rolling events by 56% (**P=0.0085) and drastically 
reduced firm adhesion in pial vessels (inhibition of 87.5%, **P=0.0060) (Table 
III). However, LFA-1 blockade at EAE onset led to a minor but significant 
reduction of Th1 cells rolling (inhibition of 41%, ***P=0.0004) and adhesion 
(inhibition of 38%, *P=0.0175) on SC vessels (Table III) without any effect in 
the chronic phase (Table III). Interestingly the pre-treatment with anti-LFA-1 
mAb did not significantly affect interactions between Th17 cells and vessels 
endothelium in SC during all EAE phases (Table IV). These data suggest 
different molecular mechanisms controlling the recruitment of Th1 and Th17 cells 
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in the SC venules during EAE, and that LFA-1 plays a selective role in the 
migration of Th1 cells during the earlier phases of EAE (preclinical phase and 
disease onset), whereas Th17 cell recruitment in the SC seems to be independent 
from LFA-1.  
 
a4 integrins differently control the recruitment of Th1 and Th17 cells in the CNS 
during EAE 
In order to understand the role of a4 integrins in the recruitment of Th1 and Th17 
cells, we pretreated T cells with blocking anti-a4 chain (clone PS/2) or anti-a4b7 
integrin (clone DATK32) antibodies before the cell injection (Fig. 16). In the 
preclinical phase of disease, blockade of a4 chain in Th1 cells led to a significant 
inhibition of rolling and adhesion events (**P=0.0025 and *P=0.0167 for rolling 
and adhesion respectively) (Table III), whereas the adhesive interactions of Th17 
cells were not affected by a4  blocking (Table IV). At the onset of EAE we 
observed a massive reduction of rolling (73% of inhibition, ***P=0.0002) and 
firm adhesion (81% of inhibition, **P=0.0013) in Th1 cells (Table III). 
Interestingly, a4 chain inhibition in Th17 cells drastically reduced stable adhesion 
by 95% (***P<0.0001) without significant effect on rolling (Table IV). 
Treatment with anti-a4 chain antibody during the chronic phase of the disease 
significantly inhibited Th1 cell rolling (35% of inhibition *P<0.05) and 
completely abrogated firm arrest (***P<0.0001) (Table III). a4 blockade in Th17 
cells during the chronic phase did not affect rolling but reduced the arrest by 65% 
(**P=0.0010) (Table IV). These data suggest different molecular mechanisms 
used by Th1 and Th17 cells to interact with endothelium in CNS vessels during 
EAE stages. In the preclinical phase of EAE a4 integrins (probably VLA-4) play 
a selectively role in the migration of Th1 cells without interfering with Th17 
recruitment, whereas at the latest stages of the disease (onset and the chronic 
phase) a4 integrins blocking prevents rolling and adhesion of Th1 cells, but 
affects only arrest in Th17 cells, suggesting different roles for a4 integrins in the 
control of Th1 and Th17 cells recruitment the CNS during EAE. 
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a4b7 specifically controls Th17 cell adhesion in inflamed CNS vessels during 
EAE  
In order to investigate a potential specific role for a4  integrins in the Th1 and 
Th17 cells recruitment during EAE, we next investigated the potential role of 
a4b7 expressed on Th1 and Th17 cells in CNS trafficking during EAE (Fig. 16). 
At the onset of the disease, Th17 cells treated with a blocking anti-a4b7 antibody 
(clone DATK32) reduced adhesion events of 74% (**P=0.0075) without any 
effect on rolling in SC vessels (Table IV). Similarly, treatment of Th17 cells with 
anti-a4b7 in the chronic phase of EAE, led to a reduction of 60% of stable 
adhesion events (***P<0.0001) while rolling was not affected (Table IV). These 
results parallel the data obtained from IVM experiments obtained after a4 chain 
blockade and underline the role of a4b7 in stable adhesion of Th17 cells in the SC 
inflamed endothelial venules. In contrast to the results obtained with Th17 cells, 
a4b7 had no role in Th1 cell rolling and adhesion in the SC during EAE  (Table 
III). Together these data suggest that VLA-4 is a major player in Th1 cells 
migration in the CNS during EAE, whereas a4b7 integrin has a more prominent 
role in Th17 cell trafficking. 
 
Two photon laser microscopy results 
Th1 and Th17 cells massively infiltrate the CNS at disease peak  
We analyzed the intraparenchymal behavior of fluorescently labeled exogenous 
Th1 and Th17 at the following time points: pre-clinical phase (9 days post-
immunization, dpi), T cells were injected 7 dpi and imaging was performed 48 
hours later; disease peak (13-14 dpi), T cells were transplanted the day after the 
onset of disease (11-12 dpi) and imaging was performed 48 hours later; chronic 
phase of EAE (22-25 dpi), T cells were injected after 3 days of chronic course 
stabilization and their motility behavior was evaluated by imaging after 48 hours. 
We first performed studies using TPLM to determine Th1 and Th17 cell 
infiltration at different time points after mice immunization with MOG35-55 
peptide. Our results showed a massive cellular infiltration at the peak of EAE in 
comparison with the other phases (Fig. 17). 
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Th1 and Th17 cells behave in a similar manner in the preclinical phase of EAE 
At the preclinical phase of the disease (mean clinical score 0 ± 0 (S.D.)) we found 
a very low number of T cells migrated into the SC. We did not observe significant 
differences in velocity and motility parameters between Th1 and Th17 cells: both 
were moving fast (around 8 µm/min) and displayed relative high levels of motility 
coefficient and low meandering index (around 0.5) suggesting random 
movements of these cells inside the SC without significant interactions with local 
cells (Fig. 18A, B, C). 
 
Th1 and Th17 cells present different motility behavior at EAE peak  
A different situation was observed at the disease peak (mean clinical score 4.5 ± 
0.5 (S.D.)). We found a massive infiltration of Th1 and Th17 cells compared to 
the preclinical phase of EAE. Both T cells displayed a reduction in the movement 
when compared to the preclinical phase of EAE. However, Th1 cells displayed a 
significant higher velocity (4.9 µm/min) when compared to Th17 cells (3.7 
µm/min) (Fig. 18D). Also, the motility coefficient was significantly higher in Th1 
cells when compared to Th17 cells (Fig. 18F). Interestingly the higher value of 
meandering index in the Th1 cells (0.52) suggests a more straight (directed) 
movement of Th1 cells compared to Th17 cells (0.40) (Fig. 18E). We 
distinguished two different behavioral patterns in Th1 cells and Th17 cells: 
approximately 80-85% of cells were rapidly moving, while the rest 10-15% was 
not moving and was anchored around a fixed point closed to vessels wall 
suggesting a potential physical contact with other cells. In the portion of moving 
Th1 cells, it was possible to distinguish between cells that were following the 
vessels wall (30%) and cells (45%) moving inside the parenchyma. However, 
Th17 showed the same behavior with the 30% of cells walking beside the vessels 
wall and the 40% of cells moving in the parenchyma. Examining in depth we 
could distinguish two different behaviors between Th1 and Th17 cells in the way 
they were moving inside the parenchyma. Th1 cells were moving straight 
covering long distances deep in SC suggesting that they were meandering 
following a chemotactic gradient, while Th17 cells seemed to move around in a 
specific volume of tissue in a “stop and go” way. These observations were 
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confirmed analyzing the fraction of cells moving deep in the parenchyma. The 
plot of displacement versus time (Fig. 19C) displayed a significant higher sloop in 
Th1 cells migration suggesting that Th1 cells were moving covering wider space 
in the parenchyma compared to Th17 cells. Chemotactic index of Th1 cells 
displayed a stable value around 0.8 during the time of observation, while Th17 
cells were inclined to decrease the ratio (Fig. 19D). These data suggested that 
Th1, unlike to Th17 cells, were meandering straight following a chemotactic 
gradient in a directed migration. Interestingly arrest index resulted significantly 
higher in Th17 cells (0.11) when compared to Th1 cells (0.07). Instantaneous 
velocity showed how Th1 cells meandered straight through the tissue in a steady 
movement, while Th17 cells displayed a “stop-and-go” mode when they migrated 
deep in the parenchyma (Fig. 19E). Representative tracks of motility behavior of 
Th1 and Th17 are displayed in Fig. 19B.  
The different motility behavior between Th1 and Th17 cells during the peak of the 
disease indicates potential different molecular mechanisms used by these cells to 
migrate in SC parenchyma. Moreover, the massive cellular infiltration during the 
peak of EAE made this disease phase a powerful experimental approach to 
investigate how blocking of VLA-4 and LFA-1 integrins could affect motility 
behavior of Th1 and Th17 cells into the SC during EAE. 
 
Th1 and Th17 cells behave similarly displaying a severe reduction in dynamics in 
the chronic phase of EAE. 
A completely different behavior of Th1 and Th17 cells was found in the chronic 
phase of EAE (mean clinical score 2.1 ± 0.7 (S.D.)). TPLM experiments 
performed at the chronic phase of EAE showed a significant reduction of mean 
velocity, meandering index and motility coefficient of both Th1 and Th17 cells 
(Fig. 18G, H, I). However, we did not observe any significant difference between 
Th1 and Th17 behavior. Both Th subsets were moving slower when compared to 
the other disease phases (around 3 µm/min) and the results obtained for the 
meandering index showed that both Th1 and Th17 cells did not have highly 
directional migration (around 0.3) (Fig. 18H). As observed at disease peak, we 
distinguished two different motility patterns in Th1: 75% of the cells were moving 
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and the rest (25%) displayed a stationary behavior. On the other hand, only the 
10% of Th17 cells appeared in an “anchored” state. All together these data 
suggest an antigen-recognition process between T cells and potential APCs in the 
SC during the chronic phase of EAE. The idea that T cells were engaged in a 
physical contact with other cells was confirmed by computation of the arrest 
coefficient that resulted statistically higher for both Th1 and Th17 cells when 
compared to the same T cells at the peak phase of disease. No differences were 
found between Th1 and Th17 cells regarding the arrest coefficient and 
instantaneous velocity at the chronic phase of EAE (Fig. 18G). 
 
LFA-1 blockade affects Th1 cell motility and cytoskeleton rearrangement  
In order to investigate a potential role of LFA-1 in the migration movement of 
Th1 cells in the CNS parenchyma, we performed TPLM experiments at the 
clinical peak of EAE analyzing the motility behavior of these cells before and 
after administration of an anti-LFA-1 blocking antibody. Neutralization of LFA-1 
activity led to a reduction of mean velocity (from 5.7 µm/min in control cells to 
3.8 µm/min in treated cells) and motility coefficient in Th1 cells (Fig. 20B, C). 
Interestingly the portion of not moving cells was not significantly modified after 
antibody treatment (11.4% in the control untreated cells and 16.7% in treated 
cells) suggesting that Th1 cells were still moving but with a reduced velocity. The 
arrest coefficient analysis confirmed these observations since the value of control 
cells (0.25%) resulted not modified after LFA-1 blocking (0.30%) (Fig. 20E). 
However, the meandering index was drastically affected by LFA-1 blocking: 
untreated Th1 cells showed a mean ratio of 0.6 with the majority of cells moving 
in straight direction, whereas anti-LFA-1 treated Th1 cells displayed a drastic 
reduction in the meandering index (0.4) (Fig. 20F). These data suggest that LFA-
1 activity controls the capacity of Th1 cells to move in a straight line following a 
chemotactic stimulus. In particular, the analysis performed on the portion of Th1 
cells moving deep in the SC parenchyma, has shown a drastic modification of 
motility behavior in Th1 cells after LFA-1 blocking treatment. The plot of the 
dynamic displacement showed a significant reduction in the curve sloop after 
antibody treatment suggesting that Th1 cells in absence of LFA-1 activity were 
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not able to walk through long-range distances covering a wide portion of volume 
of tissue (Fig. 20G). Moreover, the chemotactic index resulted significantly 
affected because treated Th1 cells showed a clear tendency to reduce the ratio 
between displacement and path length during the time of analysis suggesting a 
role of LFA-1 in the capacity of Th1 cells to proceed straight following a 
chemotactic factor (Fig. 20H). Representative tracks of motility behavior of Th1 
before and after administration of anti-LFA-1 are displayed in Fig. 20A. 
In order to investigate an active involvement of LFA-1 in cytoskeleton 
rearrangement in Th1 cell directed migration we compared the morphology of 
Th1 cells before and after the anti-LFA-1 treatment. The initial response of a cell 
to a migration-promoting agent is to polarize and extend protrusions in the 
direction of migration. These protrusions can be large, broad lamelli-podia or 
spike-like filopodia and are quantified as number of vertices for each cell 
analyzed. The volume of treated Th1 cells was significantly smaller compared to 
the control cells and the number of vertices was drastically reduced after LFA-1 
blockade (Fig. 21A, B), indicating that treated Th1 cells became rounded and 
reduce their volume because of the reduction of cytoskeleton rearrangement. 
Thus, these data show that LFA-1 blockade drastically affects the dynamics of 
Th1 cells in the SC parenchyma during EAE through the inhibition of 
cytoskeleton dynamics. In addition, the inhibition of LFA-1 leads to a velocity 
reduction in Th1 cells with consequent decreased displacement and interferes with 
their directed migration. 
 
LFA-1 controls Th17 cells motility behavior in the CNS at EAE peak  
Using TPLM approach we next investigated a potential role of LFA-1 in the 
motility behavior of Th17 cells in CNS parenchyma at EAE peak. Neutralization 
of LFA-1 activity affected the dynamics of Th17 cells leading to a reduction of 
mean velocity (from 3.5 µm/min in control cells to 2.6 µm/min in anti-LFA-1 
treated cells) and motility coefficient (Fig. 22B, C). Differently to Th1 cells that 
reduced their velocity after antibody administration, Th17 cells massively reduced 
their velocity till stop. Indeed, the portion of not moving cells in the control 
(11.0%) was drastically increased after LFA-1 blocking (47.7%) leading to an 
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increased arrest coefficient that was significant higher in the treated Th17 cells 
(0.49%) when compared to control cells (0.30%) (Fig. 22E). Moreover, the 
meandering index was reduced in Th17 cells after antibody administration (0.26) 
when compared to untreated condition (0.36) (Fig. 22F). As shown before, while 
Th1 cells showed high levels of meandering index, Th17 cells were associated to 
lower values of this ratio indicating that the majority of t cells were not moving in 
a directed way but displayed a different migration pattern. For this reason, the 
reduced meandering index in Th17 cells after LFA-1 blocking was probably due 
to the portion of not moving cells and not to a change in the motility behavior of 
moving cells. The analysis performed on the portion of Th17 cells that were still 
moving deep in the SC parenchyma after antibody administration, suggested that 
LFA-1 did not affect the motility behavior in Th17 cells after LFA-1 blocking 
treatment: we did not indeed observe significant differences in displacement and 
chemotactic index in Th17 cells before and after LFA-1 blocking (Fig. 22G, H). 
Representative tracks of motility behavior of Th17 before and after administration 
of anti-LFA-1 are shown in Fig.22A. 
The volume and the number of vertices were not altered after antibody treatment 
(Fig. 23A, B), indicating that LFA-1 activity is not involved in the cytoskeleton 
rearrangement during Th17 motility and ii) the arrest of these cells during LFA-1 
blockade is not due to a deficit in cytoskeleton dynamics. 
Taken together these data clearly show that LFA-1 drastically controls the 
movement of Th17 cells in the SC parenchyma during EAE, increasing the 
percentage of not moving cells and without interfering in their cytoskeleton 
dynamics. The inhibition of LFA-1 led to a massive reduction in the velocity 
(50% reduction) of Th17 cells without interfering with the motility behavior of 
the rest of moving cells (50%). 
 
Intrathecal injection of anti-LFA-1 antibody at disease onset inhibits EAE 
development 
The data shown above suggest that efficient effector T cell motility in the SC 
parenchyma is regulated by CNS resident cells, which are important for their 
functionality and reactivation in the CNS. For this reason, we hypothesized that 
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interfering with local T cell dynamics in the SC may limit their pathogenicity and 
may impact EAE development in immunized mice. To test this hypothesis, we 
treated MOG35-55-immunized EAE animals the day after disease onset and 4 days 
later by intrathecal injection of anti-LFA-1 antibody or control anti-Ras antibody. 
We found that local LFA-1 blockade significantly inhibited EAE development, 
when compared to mice treated with the control antibody (*P<0.05) (Fig. 24A). 
This clinical amelioration was associated with a significant reduction of both 
inflammatory cell infiltration (**P=0.0034) and demyelination (***P=0.0003) in 
anti-LFA-1 treated animals, compared to control animals (Fig. 24B). Furthermore, 
the massive microgliosis in the lumbar SC of control EAE mice was drastically 
attenuated in anti-LFA-1 treated animals (***P<0.0001) (Fig. 24C). To note, the 
second anti-LFA-1 injection 4 days after the first one further delayed the 
appearance of the clinical peak in EAE mice. However, 5-6 days after the second 
antibody injection, anti-LFA-1 treated mice showed a tendency toward disease 
worsening, compared to control mice that already developed the disease peak, 
suggesting that LFA-1 blocking probably did not eliminate pathogenic T cells 
from the SC parenchyma, but they were maintained in a more "quiescent" state in 
the SC parenchyma. Collectively, these results confirm that interfering with local 
effector T cell dynamics in the CNS parenchyma may reduce their pathogenic 
potential and may represent a useful therapeutic strategy to control autoimmune 
disease progression. 
 
a4 integrin blockade does not affect Th1 cells intraparenchymal motility behavior 
in the CNS at the peak of EAE 
We next evaluated a potential role of a4 integrin in Th1 cells movement in the SC 
parenchyma at EAE peak. We performed TPLM experiments evaluating the effect 
of anti-a4 integrin blocking antibodies on the motility behavior of Th1 cells. We 
did not observe differences in the dynamics of Th1 cells before and after 
administration of blocking antibody regarding mean velocity, meandering index, 
motility and arrest coefficient (Fig. 25A, B, C, D). These data clearly indicate that 
a4 integrin is not involved in the motility behavior of Th1 cells at EAE peak. 
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a4 integrins control Th17 cells intraparenchymal motility behavior in the CNS at 
EAE peak  
Neutralization of a4 integrin activity, differently from Th1 cells, affected the 
dynamics of Th17 cells leading to a drastic reduction of mean velocity (from 3.7 
µm/min in control cells to 2.6 µm/min in treated cells) and motility coefficient 
(from 47 µm2/min in control cells to 13 µm2/min in treated cells (Fig. 26A, C). 
Moreover, the meandering index was significantly affected by a4 blockade, with 
anti-a4 treated Th17 cells displaying a drastic reduction in the meandering index 
(0.27) (Fig. 26B). Also, the portion of not moving cells was clearly increased after 
LFA-1 blocking leading to a raise in the arrest coefficient that was significant 
higher in the treated Th17 cells (0.35%) compared to control cells (0.15%) 
(***P<0.0001) (Fig. 26D). These data suggest a selective role for a4b7 integrin 
in the control of the motility behavior of Th17 cells inside SC parenchyma. 
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Intrathecal injection of anti-a4b7 antibody at disease onset ameliorates EAE 
severity  
We hypothesized that a4b7 integrin blockade may specifically interfere with local 
dynamics of Th17 cell subset in the SC and may impact EAE development in 
immunized mice. To test this hypothesis, we treated MOG35-55-immunized EAE 
animals the day after disease onset and 3 days later by intrathecal injection of anti-
a4b7 antibody or control anti-Ras antibody. We found that local a4b7 blockade 
significantly inhibited EAE development, when compared to mice treated with the 
control antibody (*P<0.05) (Fig. 27). To note, the clinical amelioration remained 
stable during all observation time suggesting an important role for autoreactive 
Th17 cells not only in EAE induction but also in the maintenance of 
neuroinflammatory milieu. 
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Figure 11. Intracellular staining of Th1 and Th17. Intracellular IL-17 and IFN-
γ cytokine expression was analyzed by FACS.  
 
 IL-17 
IFN-γ 
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    A                                                                B 
 
Figure 12. Adhesion molecule expression in Th1 and Th17 cells. Samples were 
analyzed by flow cytometry. Percentage of positive expression of adhesion 
molecules was evaluated. Th17 cells showed a significantly lower percentage of 
expression for L-selectin compared to Th1 cells, whereas a4b7 integrin 
expression was higher on Th17 compared to Th1 cells (A). MIF of LFA-1 was 
statistically significantly higher on Th1 cells (B). Data are expressed as mean ± 
SD. Statistics were calculated using Mann-Whitney test (*** P<0.0001).  
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Figure 13. Vessel morphology during different EAE phases. Representative 
images of the spinal cord pial vessels during the pre-clinical phase, disease peak 
and chronic phase were taken at IVM to evaluate morphological changes in the 
course of pathology. Vessels were labeled with high molecular weight dextran. At 
the disease peak are reported two representative images taken before and after 
intravenously injection of labeled T cells. Graph reports the diameters, express in 
µm, of at least 75 vessels for each condition at different time point. Statistics were 
calculated using ANOVA one way test (*P<0.05).  
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Figure 14. Time course of interactive events of Th1 and Th17 cells during 
different EAE phases. Two representatives graphs show the variations in the 
rolling and adhesion components for Th1 and Th17 cells during the course of the 
pathology. Graphs were obtained from the comparison of the interactive events of 
Th1 and Th17 at day 7, 14 and 21 post immunization and are expressed as  
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percentage on total cells. Data are expressed as mean ± SEM. Statistics were 
calculated using Mann-Whitney test (*P<0.05; **P<0.005). 
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Figure 15. LFA-1 blocking affects early phases of Th1 interactions in the 
inflamed SC pial vessels during EAE. MOG35-55-specific Th1 or Th17 cells were 
injected in EAE mice in the preclinical phase (7 dpi), at disease onset (14 dpi) and 
in the chronic phase (21 dpi) directly before imaging. A digital videotape of 
control cells interactions in the inflamed SC pial vessels was acquired. 
Afterwards, a tranche of anti-LFA-1 treated cells was injected. Digital videotape 
of treated cells was registered and manually analyzed. Data are expressed in mean 
± standard error mean (SEM). Statistics were calculated with a one sample t test 
to the hypothetical control value fixed at 100. Two tailed test (*P<0.05; 
**P<0.005; ***P<0.0001). 
CTRL Anti-LFA-1 
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Figure 16. a4 integrins blockade differently affect Th1 and Th17 cell 
adhesion in inflamed SC vessels during EAE. MOG35-55-specific Th1 or Th17 
cells were injected in EAE mice in the preclinical phase (7 dpi), at disease onset 
(14 dpi) and in the chronic phase (21 dpi) directly before imaging. A digital 
videotape of control cells interactions in the inflamed SC pial vessels was 
acquired. Afterwards, a tranche of anti-a4 or anti-a4b7 treated cells was injected. 
Digital videotape of treated cells was registered and manually analyzed. Data are 
expressed in mean ± standard error mean (SEM). Statistics were calculated with a 
one sample t test to the hypothetical control value fixed at 100. Two tailed test 
(*P<0.05; **P<0.005; ***P<0.0001). 
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Figure 17. Quantification of Th1 and Th17 accumulation in the SC 
parenchyma at different disease stages. MOG35-55-specific Th1 and Th17 cells 
were co-injected in EAE mice in the preclinical phase (7 dpi), at disease peak (11-
14 dpi) or in the chronic phase (22-25 dpi). 48 hours later, TPLM imaging was 
performed. Cells were subsequently quantified by manual counting in field 
(volume) of acquisition. Data are the mean ± SEM of 6 different fields from 3 
independent experiments. 
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Figure 18. Th1 and Th17 cell dynamics during EAE phases in the SC 
parenchyma. Mice were immunized with MOG35-55 peptide and scored for EAE. 
MOG35-55-specific Th1 and Th17 cells were co-injected in EAE mice in the 
preclinical phase (7 dpi), at disease peak (11-14 dpi) or in the chronic phase (22-
25 dpi). 48 hours later, TPLM imaging was performed. (A) Mean velocity, (B) 
Meandering index and (C) Motility coefficient of Th1 and Th17 cells in the 
preclinical phase of the disease (7 dpi). (D) Mean velocity, (E) meandering index 
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and (F) motility coefficient of Th1 and Th17 cells at the peak of the disease (11-
14 dpi). Massive infiltration of Th1 and Th17 was observed. (G) Mean velocity, 
(H) meandering index and (I) motility coefficient of Th1 and Th17 cells in the 
chronic phase of the disease (22-25 dpi). Data are expressed as mean ± SD. 
Statistics were calculated using Mann-Whitney test (***P< 0.0001). 
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Figure 19. Comparison of autoreactive Th1 and Th17 dynamics in the SC 
parenchyma at EAE peak.   MOG35-55-specific Th1 and Th17 cells were co-
injected in EAE mice at disease peak (11-14 dpi). 48 hours later, TPLM imaging 
was performed. Comparison of percentage of total Th1 and Th17 cells that were 
moving in the parenchyma, along vessels wall or not moving cells. Three-
dimensional spatial position of each cell was detected based on centroid 
fluorescence intensity (A). Representative images of Th1 and Th17 cells moving 
in the deep SC parenchyma of EAE mice at disease peak. The images are all 3D 
reconstructions that include the vasculature (red), CMAC-labeled Th1 cell (blue) 
and CFSE-labeled Th17 cell (green). Green lines tracks motile T cells (scale bar: 
50 µm). Cells were tracked over time (30 min of acquisition) manually (B). Mean 
displacement (C) and chemotactic index (D) of Th1 and Th17 cells moving in the 
deep parenchyma of the SC. Instantaneous velocities of 3 representative Th1 (left 
panel) and Th17 cells (right panel) moving in the SC parenchyma. Cells moving 
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below 2 µm/min were considered stopped (E). Multidimensional imaging was 
performed by Imaris. Data are the mean ± SEM of 100 cells from 3 independent 
experiments. In (C) and (D) was applied a linear regression and compared the 
slopes. 
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Figure 20. LFA-1 blocking strongly affects autoreactive Th1 cell dynamics in 
the SC parenchyma of EAE mice at disease peak. Th1 cell dynamics were 
analyzed in the SC of EAE mice at disease peak before (CTRL) and after 
application of anti-LFA-1 mAb on the exposed SC using TPLM approach.  
Representative images of Th1 moving in the SC parenchyma before and after 
antibody treatment. Cell tracks (green lines) are also shown (scale bar: 50 µm; red 
color: blood vessel) (A). Mean velocity (B), motility coefficient (C), dynamic 
properties (D), arrest coefficient (E) and meandering index (F) of the whole Th1 
cell population in the SC parenchyma in the presence or absence of anti-LFA-1 
antibody. Displacement (G) and ratio between displacement and path length 
during the time of analysis (H) of Th1 cells moving in the deep parenchyma of the 
SC. In all graphs, data are the mean ± SEM of 100 cells from 3 independent 
experiments. Statistics were calculated using Mann-Whitney test (***P<0.0001). 
In (G) and (H) was applied a linear regression and compared the slopes 
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Figure 21. LFA-1 blockade affects Th1 cell morphology in the SC 
parenchyma at disease peak. Intraparenchymal Th1 cell morphology was 
determined before (CTRL) and after application of an anti-LFA-1 mAb antibody 
on the exposed SC. Cell volume (A) and number of vertices (B) of Th1 cells 
before and after LFA-1 inhibition Representative images of Th1 cells before and 
after anti-LFA-1 treatment. Note the presence of highly polarized cells before 
antibody application (left panel, white arrows) and the predominant round-like 
cell morphology induced by LFA-1 blocking (right panel) (scale bar: 10 µm; red 
color: blood vessel) (C). Data are the mean ± SEM of 100 cells from 3 
independent experiments. Statistics were calculated using Mann-Whitney test 
(*** P<0.0001). 
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Figure 22. LFA-1 inhibition reduces autoreactive Th17 cell motility in the SC 
at disease peak. Th17 cell dynamics were analyzed in the SC of EAE mice at 
disease peak before (CTRL) and after application of anti-LFA-1 mAb on the 
exposed SC using TPLM. Representative images of Th17 cells moving in the SC 
parenchyma before (CTRL) and after antibody treatment. Cell tracks (green lines) 
are also shown (scale bar: 50 µm; red color: blood vessel) (A). Mean velocity (B), 
motility coefficient (C), dynamic properties (D), arrest coefficient (E) and 
meandering index (F) of Th17 cells are shown in the presence or absence of anti-
LFA-1 antibody. Mean displacement (G) and chemotactic index (H) of Th17 cells 
moving in the SC parenchyma after antibody treatment. Data are the mean ± SEM 
of 100 cells from 3 independent experiments. Statistics were calculated using 
Mann-Whitney test (*P<0.05; ***P<0.0001). In (E) and (F) it was applied a 
linear regression and slopes were compared.  
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Figure 23. Morphology of Th17 cells in the SC parenchyma is not affected by 
anti-LFA-1 treatment. The cell volume (A) and the number of vertices (B) of 
intraparenchymal Th17 cells were calculated before and after anti-LFA-1 mAb 
treatment of the SC of EAE mice at disease peak. LFA-1 blocking had no effect 
on Th17 cell cytoskeletal organization, compared to control condition. 
Representative images of Th17 cells before (left panel) and after anti-LFA-1 
treatment (right panel) (scale bar: 10 µm; red color: blood vessel) (C). Data are 
the mean ± SEM of 100 cells from 3 independent experiments. Statistics were 
calculated using Mann-Whitney test. 
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Figure 24. Intrathecal injection of an anti-LFA-1 blocking antibody 
ameliorates EAE severity. C57Bl/6 mice were immunized with MOG35-55 
peptide and injected in the cisterna magna the day after disease onset (12 dpi) and 
4 days later (red arrows) with 10 µl of PBS containing 50 µg of anti-human Ras 
(CTRL) or anti-LFA-1 blocking antibody. Mice were followed until 40 dpi and 
scored daily for disease activity. Data are the mean ± SEM of 16 mice/conditions 
from 4 independent experiments. Statistics were calculated using Mann-Whitney 
test (*P<0.05) (A). Neuropathology of EAE mice treated with anti-LFA-1 
blocking antibody. Mice were sacrificed 3 days after the first antibody injection 
(14 dpi), and SCs were analyzed for the presence of inflammatory infiltrates and 
demyelination with hematoxylin/eosin and luxol fast blue staining respectively (4-
6 cross sections of SC per mouse, n = 3 mice). Representative consecutive SC 
sections of anti-Ras (CTRL) or anti-LFA-1-treated animals are shown. 
Quantitative analysis of infiltrated cells and demyelination area for each condition 
are expressed as mean ± SEM. Statistics were calculated using Mann-Whitney test 
(**P < 0.005; ***P < 0.0001). All panels shown are 5x magnification, scale bar = 
200 µm (B). Quantitative analysis of microglial cells for each condition to 
determine the total number of Iba-1+ cells and the area occupied by cell soma (4-
6 cross sections of SC per mouse, n = 3 mice). Representative images of Iba1+ 
microglia in mice treated with an isotype control or anti-LFA-1 antibody. Error 
bars indicate SEM (***P<0.0001). Left, 5x magnification; right, 10x 
magnification, scale bar = 200 µm (C). 
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Figure 25. a4 integrins do not affect Th1 cells intraparenchymal motility 
behavior in the CNS at the peak of EAE. Th1 cell dynamics were analyzed in 
the SC of EAE mice at disease peak before (CTRL) and after application of anti-
a4 mAb on the exposed SC using TPLM. (A) Mean velocity, (B) meandering 
index, (C) motility coefficient and (D) arrest index. Data are expressed as mean ± 
SEM. Statistics were calculated using Mann-Whitney test. 
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Figure 26. a4 integrins control Th17 cells intraparenchymal motility 
behavior in the CNS at the peak of EAE. Th17 cell dynamics were analyzed in 
the SC of EAE mice at disease peak before (CTRL) and after application of anti-
a4 mAb on the exposed SC using TPLM. (A) Mean velocity, (B) meandering 
index, (C) motility coefficient and (D) arrest index. Data are expressed as mean ± 
SEM. Statistics were calculated using Mann-Whitney test (***P<0.0001).  
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Figure 27. Intrathecal 
injection of anti-a4b7 
blocking antibody 
reduces EAE 
progression in MOG35-
55- immunized mice. 
C57Bl/6 mice were 
immunized with MOG35-
55 peptide and injected in 
the cisterna magna the 
day after disease onset 
(12 dpi) and 3 days later 
(red arrows) with 10 µl 
of PBS containing 50 µg 
of anti-human Ras 
(CTRL) or anti-a4b7 blocking antibody. Mice were followed until 40 dpi and 
scored daily for disease activity. Data are the mean ± SEM of 16 mice/conditions 
from 2 independent experiments. Statistics were calculated using Mann-Whitney 
test (*P<0.05). 
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Table I. Diameter, hemodynamics, and rolling velocities of Th1 and Th17 
cells in the SC at the different phases of EAE. The diameters of pial vessels 
maximum velocity (Vmax), mean blood flow velocity (Vm), wall shear stress 
(WSS) and rolling velocities for the injected T cells were calculated during the 
different phases of EAE. The velocity of rolling cells was measured by digital 
frame-by-frame analysis of videotapes. Vroll are presented as median. Data are 
expressed as arithmetic mean ± SD. 
 Diameter 
(µm) 
Vmax 
(µm/s) 
Vm 
(µm/s) 
WSS 
(dyne/cm2) 
Vroll 
(µm/s) 
Preclinical 24.6 ± 6.8 1701 ± 349 1097 ± 115 9.3 ± 3.9 31.3 
24.6 ± 6.8 1528 ± 500 1027 ± 415 9.4 ± 6.6 31.1 
Onset 31.8 ± 
10.3 
1616 ± 382 882 ± 207 4.8 ± 1.1 33.6 
31.8 ± 
10.3 
1099 ± 222 598 ± 113 3.2 ± 0.4 45.6 
Chronic 22.0 ± 6.2 1558 ± 316 1133 ± 206 10.7 ± 5.3 45.8 
22.0 ± 6.2 1654 ± 280 1055 ± 148 9.8 ± 4.1 53.3 
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Table II. Percentage of rolling and adhesion events of Th1 and Th17 cells in 
the SC at the different phases of EAE. The velocity of rolling cells was 
measured by digital frame-by-frame analysis of videotapes. Data are mean ± SEM 
for the percentages of rolling and arrest.  
 
 
 Score Nr. 
animals/ 
/venules 
% Rolling % 
Adhesion 
Preclinical Th1 0 ± 0 3/13 26.5 ± 2.8 4.4± 0.8 
Th17 0 ± 0 3/13 19.4 ± 1.8 1.4 ± 0.3 
Onset Th1 2.2±0.3 3/14 21.0 ± 2.0 2.2 ± 0.3 
Th17 2.2±0.3 3/14 26.1 ± 2.1 3.8 ± 0.6 
Chronic Th1 2 ± 0 3/16 25.5 ± 1.9 2.3 ± 0.4 
Th17 2 ± 0 3/16 20.0 ± 1.8 2.8 ± 0.7 
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  Score Nr. 
animals/
venules 
% Rolling % Adhesion 
 
 
Preclinical 
CTR 0 ± 0 3/13 28.5 ± 3.8 6.8 ± 1.4 
anti-a4 0 ± 0 3/13 12.2 ± 4.0 2.5 ± 0.8 
CTR 0 ± 0 3/18 31.4 ± 8.0 4.3 ± 1.7 
anti-LFA-1 0 ± 0 3/18 12.3 ± 3.0 0.6 ± 0.6 
 
 
Onset 
CTR 2.3±0.6 3/14 10.2 ± 2.5 1.4 ± 0.6 
anti-a4 2.3±0.6 3/14 3.4 ± 1.8 0.2 ± 0.2 
CTR 2 ± 0 3/15 34.1 ± 5.8 6.3 ± 0.9 
anti-a4b7 2 ± 0 3/15 29.1 ± 3.6 6.0 ± 0.5 
CTR 2.5±0 3/19 25.9 ± 2.7 2.1 ± 0.5 
 anti-LFA-1 2.5±0 3/19 15.1 ± 2.2 1.0 ± 0.3 
 
 
Chronic 
CTR 1.7±0.6 3/16 17.3 ± 4.8 2.1 ± 1.1 
anti-a4 1.7±0.6 3/16 11.3 ± 1.8 0.0 ± 0.0 
CTR 2±0 2/18 31.7±1.2 1±0.5 
anti-a4b7 2±0 2/18 30.8±1.8 0.85±0.4 
CTR 2.2±0.3 3/15 22.4 ± 3.1 1.5 ± 0.6 
anti-LFA-1 2.2±0.3 3/15 19.6 ± 2.3 1.5 ± 0.5 
Table III. Percentage of rolling and adhesion events of Th1 cells treated with 
blocking antibodies. Data are arithmetic mean ± SEM for the percentages of 
rolling and arrest.  
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  Score Nr. 
animals 
/venules 
% 
Rolling 
% Adhesion 
 
 
Preclinical 
CTR 0 ± 0 3/13 13.3 ± 1.8 1.6 ± 0.7 
anti-a4 0 ± 0 3/13 11.0 ± 1.2 1.5 ± 0.5 
CTR 0 ± 0 3/15 19.5 ± 3.6 1.1 ± 0.4 
anti-LFA-1 0 ± 0 3/15 14.5 ± 4.5 1.3 ± 0.8 
 
 
Onset 
CTR 2 ± 0 3/14 30.4 ± 4.2 1.8 ± 1.4 
anti-a4 2 ± 0 3/14 30.8 ± 6.9 0.4 ± 0.4 
CTR 2 ± 0 3/24 38.7 ± 4.4 5.0 ± 1.3 
anti-a4b7 2 ± 0 3/24 40.4 ± 2.5 2.4 ± 1.0 
CTR 2 ± 0 3/10 22.7 ± 4.0 5.5 ± 1.5 
 anti-LFA-1 2 ± 0 3/10 20.7 ± 3.7 4.1 ± 1.1 
 
 
Chronic 
CTR 2 ± 0 3/16 13.8 ± 1.8 1.4 ± 0.4 
anti-a4 2 ± 0 3/16 14.5 ± 3.6 0.7 ± 0.2 
CTR 2 ± 0 3/12 27.3 ± 4.9 5.0 ± 1.3 
anti-a4b7 2 ± 0 3/12 26.4 ± 6.2 0.6 ± 0.5 
CTR 1.5±0.7  3/153/153/1533/1533/1 3/15 24.5 ± 2.8 3.7 ± 1.2 
anti-LFA-1 1.5±0.7 3/15 23.4 ± 5.7 2.6 ± 0.7 
Table IV. Percentage of rolling and adhesion events of Th17 cells treated 
with blocking antibodies.  Data are arithmetic mean ± SEM for the percentages 
of rolling and arrest. 
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Discussion 
Lymphocytes are constantly in motion, trafficking passively in the blood, 
migrating in lymphoid or non-lymphoid target organs where they can be activated 
by migrated or resident APCs. Several prerequisites must be met for leucocytes to 
reach a target site. Initially, they need to adhere to the activated endothelium in 
post-capillary venules, a process that is governed by the multistep adhesion 
cascade. This cascade consists of selectin-mediated tethering and rolling, firm 
adherence facilitated by activated integrins, and transendothelial migration. Auto-
reactive T cells trafficking in the CNS represents a critical event in the 
pathogenesis of EAE, the animal model of MS. In this study, we have tested the 
involvement of aLb2 (LFA-1), a4b1 (VLA-4) and a4b7 integrins in Th1 and 
Th17 cells trafficking in MOG35-55 peptide immunized mice during EAE.  
Our results have shown that Th17 cells display higher levels of a4 integrins and 
lower L-selectin expression compared to Th1 cells, suggesting these cells are 
more activated and may have increased propensity to migrate to sites of 
inflammation (Chen J et al, J Immunol, 2006: Ley K et al, Nat Rev Immunol, 
2004). Mean fluorescence intensity of LFA-1 was significantly higher on Th1 
cells compared to Th17 cells, whereas a4b7 integrin expression was significantly 
higher on Th17 cells compared to Th1 cells. Our flow cytometry data suggest a 
potential different integrin pattern used by Th1 and Th17 cells during their 
migration into the inflamed tissues. 
By using IVM we compared Th1 and Th17 cell adhesion in the SC venules during 
EAE phases: preclinical phase, disease onset and chronic phase. We observed that 
Th1 cells show higher capacity to roll and arrest on CNS endothelium in pial 
venules when compared to Th17 cells at the preclinical phase of EAE. This data 
suggest that Th1 cells have a higher capacity to migrate inside the SC during early 
disease when compared to Th17 cells. These data are in agreement with previous 
studies showing that Th1 effector cells infiltrate the non-inflamed CNS to initiate 
inflammation that facilitates subsequent recruitment of Th17 cells in a transfer 
EAE model (O’Connor R. et al, J Immunol, 2008). However, at disease onset 
Th17 cells displayed equal capacity to roll but significantly higher adhesive 
capacity in inflamed SC venules compared to Th1 cells, suggesting a major role 
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of Th17 cell trafficking during clinical disease. During the chronic phase of EAE 
we observed that Th1 cells were more engaged in adhesive interactions compared 
to Th17 cells, suggesting a role for these cells in disease progression. These data 
suggest different roles and molecular mechanisms used by Th1 and Th17 cells to 
migrate into the SC and contribute to disease induction and progression. It was 
previously shown that human and murine Th1 and Th17 cells express different 
patterns of integrins and chemokine receptors that can selectively drive these cells 
into the brain or SC. For example, CXCR3 and CCR5 are preferentially express 
on Th1 cells whereas CCR6 is highly expressed on Th17 cells (Prendergast CT et 
al. Endocr. Metab. Immune Disord Drug Targets, 2009). Moreover, parenchymal 
inflammation in the brain but not SC is dependent on the presence of a high 
Th17:Th1 ratio suggesting that Th1 and Th17 migration capacity and vascular 
factors may determine lesion localization (Stromnes IM et al., Nat Med, 2008).  
The results obtained by IVM performed using blocking anti-integrin antibodies, 
showed that VLA-4 is the major adhesion molecule involved in Th1 cell adhesion 
in SC venules during all disease phases, whereas LFA-1 had a minor role only 
during the preclinical phase and disease onset. Our data are in agreement with 
previous results showing a major role for VLA-4 in the migration of Th1 cells in 
the SC and that a4 blockade inhibits the development of the disease interfering 
with the migration of Th1 cells both in the brain and in the SC in a transfer EAE 
model (Glatigny S, J Immunol, 2011; Rothhammer V et al., J Exp Med, 2011).  
a4b7 blockade prevented firm adhesion of Th17 cells in the SC vessels during 
clinical EAE, suggesting a prominent role for this integrin in Th17 cell adhesion. 
Mice transferred with encephalitogenic Th17 cells developed atypical EAE in the 
presence of anti-a4 treatment, showing signs of cerebral rather than SC disease 
with severe gait ataxia or hemiparesis, suggesting that a4 blockade inhibited Th17 
cell-dependent pathology in the SC but not in the brain. (Rothhammer V et al, J 
Exp Med, 2011). Previous studies have also shown that Th17 cells are recruited to 
the CNS in a LFA-1 dependent manner (Yamazaki T et al, J Immunol, 2008; 
Rothhammer V et al., J Exp Med, 2011). In fact, Rothhammer and colleagues 
have shown that CD11a (the αL subunit of LFA-1) blockade combined with α4 
inhibition totally prevented Th17 cell entrance in the brain and blocked disease 
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development (Rothhammer V et al, J Exp Med, 2011). A role for a4b7 integrin 
was previously shown by Kanwar and coworkers using a chronic form of EAE in 
which the administration of anti-a4 integrin antibody as well as b7 blockade 
reduced EAE (Kanwar RJ et al., J Neuroimmunol, 2000). Also, blockade of 
Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), the main 
a4b7integrin ligand, prevented development of disease in a chronic-non remitting 
form of EAE actively induced by immunization with MOG35-55 peptide. 
MAdCAM-1 expression was found on specialized high endothelial venules 
(HEV) as well as at chronic inflammation sites (Rossi B et al., J Leuk Biol, 2010). 
In our IVM study we did not determine the role of MAdCAM-1 and further 
studies are needed to clarify the role of this molecule in T cell adhesion in CNS 
microcirculation. Moreover, our data showing a role for b7 integrin chain were 
obtained in a chronic EAE model induced with MOG35-55 peptide, whereas the 
role of a4b7 integrins and MAdCAM-1 in relapsing-remitting EAE is unclear 
(Engelhardt B et al., J Clin Invest, 1998). 
Surprisingly, our data showed that Th17 cell adhesion in inflamed SC pial vessels 
is independent of LFA-1 and a4 at the preclinical phase of disease. T cell 
adhesion during early disease needs to be further investigated to identify the 
molecular mechanisms specifically involved in the recruitment of 
encephalitogenic Th17 cells during early phase of EAE. Previous studies have 
shown that melanoma cell adhesion molecule (MCAM) (CD146) is involved in 
rolling, adhesion and transmigration of T cells in the inflamed CNS during EAE 
(Larochelle C, Brain, 2012). Moreover, our laboratory has also shown that 
endothelial selectins and their mucin ligands such as PSGL-1 and TIM-1 are 
involved in Th1 and Th17 cell migration into the inflamed brain (Piccio L et al., J 
Immunol, 2002; Rossi B et al., J Leuk Biol 2010; Angiari S et al., Immunity 2014; 
Angiari S and Constantin G, Trends Mol Med, 2014). Thus, we speculate that 
endothelial selectins and other molecules from the immunoglobulin superfamily 
may be responsible for the early recruitment of Th17 cells in the inflamed CNS. 
The activation and trafficking of T cells in autoimmune diseases is not fully 
understood.  In recent years TPLM has been used extensively to study the motility 
behavior of T cells inside lymphoid and non-lymphoid tissues during autoimmune 
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responses. TPLSM is advantageous because it achieves deep tissue penetration 
and high resolution with low phototoxicity, making it ideal to visualize immune 
system cells in living animals and to provide dynamic views of leukocytes. For 
example, TPLSM has shown that following extravasation in the LNs, T cells 
initially move at high velocity, displaying a random walk or directed migration 
pattern to facilitate antigen surveillance (Miller MJ et al., Proc Natl Acad Sci 
USA, 2003; Calahan MD and Parker I, Ann Rev Immunol, 2008; Rossi B and 
Constantin G, Front Immunol, 2016). If migrating T cells come into direct contact 
with APCs in the lymph nodes, their dynamic behavior undergoes changes such as 
reduced motility or organization into clusters, leading to cell activation and 
proliferation. These TPLM results have helped to explain how lymphocytes 
optimize their chances of encountering rare cognate antigens and initiate adaptive 
immune responses by their fast and stochastic motility (Bousso P, Nat Rev 
Immunol, 2008; Rossi B and Constantin G, Front Immunol, 2016).  
The reactivation of primed T cells in the CNS is necessary for the initiation of 
inflammatory responses and requires physical contact between T cells and local 
APCs, which present MHC-II associated peptides, resulting in inflammation, 
demyelination and axonal damage (Goverman, J. 2009. Nat. Rev. Immunol. 2009). 
In the last decade, TPLSM has revealed the motility behavior of migrating T cells 
in the CNS, and their reactivation inside the SC parenchyma, which is the main 
site of CNS inflammation in most EAE models in mice. Importantly, T cells 
interact with APCs in the subarachnoid space during the early stages of EAE, and 
these contacts seem critical for T cell reactivation and expansion in the CNS 
(Bartholomäus I et al., Nature 2009; Kivisäkk P, Annals Neurol, 2009). It was 
demonstrated that CD4+ T-cell motility is actively promoted in the SC during 
EAE (Siffrin V et al., Brain, 2009), facilitating an efficient and rapid screening of 
the mainly professional APCs, integrating relevant stimulatory, costimulatory and 
regulatory signals (Serafini B et al., Am J Pathol 2000; Serafini B et al., J 
Neuropathol Exp Neurol, 2006). The MHC-II+ APCs located in the CNS during 
EAE mainly comprise perivascular macrophages and DCs, which induce local 
reactivation of primed myelin-reactive T cells resulting in CNS inflammation and 
EAE progression (Rossi B and Constantin G, Front Immunol, 2016). 
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Previous TPLM studies have shown that autoreactive effector T cells move 
seemingly unhindered and fast through the CNS with two distinct migratory 
patterns: a major proportion of the autoimmune T cells moved rapidly, randomly 
and in a “stop and go” mode through the compact white and grey matter, while the 
rest of the cells were attached and moved around a fixed anchor point (Kawakami 
N et al., J. Exp. Med, 2005). However, how T cell subsets move inside the 
inflamed CNS and the molecular mechanisms involved in the dynamics of 
autoreactive T cells in the CNS parenchyma during the disease are largely 
unknown. In our experiments for this PhD thesis we studied Th1 and Th17 cell 
dynamics in SC at different time points during EAE: the preclinical phase, the 
disease peak and the chronic phase of disease. Moreover, we characterized, for the 
first time, the role of integrins in the motility behavior of Th1 and Th17 cells in 
SC parenchyma during EAE.  
At the preclinical phase of EAE, we found a low number of T cells entering the 
CNS, with Th1 cells being in higher number comparing to Th17 cells (ratio 2/1 
between Th1 and Th17 cells). The higher accumulation of Th1 in the SC 
parenchyma in TPLM settings was supported by IVM experiments showing a 
greater capacity to adhere in the meningeal vessels exerted by Th1 cells when 
compared to Th17 cells in the preclinical phase of disease. Moreover, in a transfer 
EAE model it was previously shown that only Th1 cells access the non inflamed 
CNS and that Th17 cells appear in the CNS after Th1 cells induce the EAE lesion. 
These data suggest that Th1 cells initiate EAE upon passive transfer and promote 
subsequent recruitment of Th17 cells to the CNS (O’Connor RA et al., J Immunol, 
2008). Notably, in our experiments T cells were not uniformly distributed along 
the volume of tissue analyzed, but both Th subsets accumulated in small groups in 
discrete SC areas, suggesting preferential points of entrance and 
microenvironmental positioning for this cells in the preclinical phase of EAE. 
Interestingly, we observed that Th1 cells were distributed deeply in the 
parenchyma without clustering organization, whereas a high percentage of Th17 
cells were moving in the perivascular area following the vessels wall. We did not 
observe significant differences in velocity and motility parameters between Th1 
and Th17 lymphocytes, suggesting some common migration mechanisms inside 
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the inflamed SC at this stage of disease. Both Th1 and Th17 cells were moving 
fast and displayed a relative high levels motility coefficient suggesting random 
movements of these cells inside the SC parenchyma, suggesting low engagement 
with APCs. Our data are supported by previous studies showing that the first T 
cells entering the CNS immediately after transfer are in a very few numbers when 
compared to a second massive inflammatory cells accumulation coinciding with 
the onset of clinical symptoms. Indeed, it has been previously shown that the 
majority of the T cells during the preclinical phase of EAE remain confined 
within secondary immune organs (such as spleen) and blood before they invade 
the SC (Flügel A et al., Immunity, 2001). Moreover, the first T cells entering the 
CNS are able to produce high amounts of pro-inflammatory cytokines 
independent on antigen recognition (supporting the random movements displayed 
by Th1 and Th17 cells in ours TPLM experiments). These cells are able to create 
an immune permissive setting the stage for the second inflammatory wave, which 
contains antigen-specific cells as well as non-specific recruited immune cells 
(Flügel A et al., Immunity, 2001). However, these “pioneer T cells” do not cause 
any immediate clinical or histological changes, but rather seem to prepare the 
CNS tissue for the second wave of invading effector cells, which coincides with 
the onset of clinical symptoms (Wekerle et al., Trends Neurosci, 1986; Hickey et 
al., J Neurosci, 1991). 
At disease peak we found a massive infiltration of Th1 and Th17 cells compared 
to the preclinical phase of EAE. We found similar density of Th1 and Th17 cells 
the SC suggesting an equal capacity of these cells to invade the inflamed CNS at 
disease peak. Both T cells displayed a reduction in the movement compared to the 
preclinical phase, nevertheless Th1 cells displayed a higher velocity and motility 
when compared to Th17 cells. Both Th subsets presented two different motility 
behavior: the majority of cells were rapidly moving, while the rest was stationary 
around a fixed point closed to vessels wall suggesting a potential physical contact 
with perivascular phagocytes/APCs (Odoardi F et al., Proc Natl Acad Sci U.S.A., 
2007; Pesic M. et al, Clin investigation, 2013; Bartholomäus I et al., Nature, 
2009). Our data are supported by previous TPLM studies on spinal cord slices 
obtained at the onset of EAE in a rat model (Kawakami N et al., J Exp Med, 
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2005). These results showed that MBP-specific effector T cells move through the 
CNS with two distinct migratory patterns: ~65% of the cells moved rapidly and 
randomly through the compact white and gray matter, whereas the remaining 
~35% appeared tethered to a fixed point, suggesting the formation of immune 
synapses (Kawakami N et al., J Exp Med, 2005). In fact, pretreatment of the 
spinal cord tissue with neutralizing anti-MHC-II monoclonal antibodies 
significantly reduced the number of arrested autoreactive T cells (Kawakami N et 
al., J Exp Med, 2005). In contrast to the MBP-specific T cells, OVA-specific T 
cells did not form synapse-like contacts in the spinal cord in this model but 
invaded the CNS and moved rapidly through the tissue. More recent in vivo 
TPLM studies based on laminectomy in the lumbar spinal cord of a rat EAE 
model were used to visualize T cells within the meningeal areas and the adjacent 
white matter (Odoardi F et al., Proc Natl Acad Sci U.S.A., 2007). These studies 
revealed that an intravenous infusion of soluble MBP during the acute EAE phase 
caused rapid antigen uptake by APCs in the CNS, resulting in the deceleration of 
MBP-specific T cells, a higher frequency of T cell immobilization, a stronger 
activating state and the enhanced production of inflammatory cytokines (Odoardi 
F et al., Proc Natl Acad Sci U.S.A., 2007). In this EAE model, BBB leakage 
allowed the uptake of circulating antigen that was quickly processed by CNS cells 
expressing MHC-II, which were preferentially located in meningeal areas and in 
the vicinity of vessels, i.e. the regions mainly infiltrated by T cells. However, 
effector and resting memory T cells specific for the non-CNS antigen OVA were 
also recruited to EAE lesions and moved there without contacting APCs. As 
shown for the MPB-specific T cells, the OVA-specific T cells were activated and 
arrested following the intravenous infusion of ovalbumin, which increased the 
severity of disease symptoms. This suggested that effector T cells home towards 
acute EAE lesions and can be reactivated locally by exogenous antigen regardless 
of the specificity of the intruding T cell population (Odoardi F et al., Proc Natl 
Acad Sci U.S.A., 2007).  
In our experiments, 30% of moving Th1 and Th17 cells at disease peak was 
walking beside the vessels wall and the 40-45% of cells was moving in the 
parenchyma. Previous TPLM experiments demonstrated that CD4+ T-cell 
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compartmentalization in the parenchyma along CNS vessels is dependent on 
CXCR4 functioning, whereas classical adhesion molecules seem to have no major 
function in this process (Siffrin V et al., Brain, 2009). Pretreatment with a 
CXCR4 antagonist led to a shift of CD4+ T cells from a perivascular motility 
pattern to intraparenchymal invasion, resulting in disorganization of the vessel 
cuffs. These data suggest that the compartmentalization of CD4+ T-cells in 
vessels proximity is actively promoted, and can facilitate efficient and rapid 
screening of perivascular professional APCs (Siffrin V et al., Brain, 2009). We 
also observed that Th1 cells were mainly moving in a straight direction covering 
long distances deep in the SC parenchyma in a constant motion following the 
same direction, while Th17 cells moved in a specific volume of tissue displaying 
a stop-and-go motility type. In particular, Th1 cells seemed to move preferentially 
along the axis of the SC in the same direction on the main SC central vein. Similar 
observation was recently made by Kim and colleagues who reported that effector 
T cells migrate preferentially along the rostrocaudal SC axis with confined lateral 
movement in the thoracic area during EAE (Kim JV et al., J Immunol Methods, 
2010). 
TPLM experiments performed during the chronic phase of EAE showed a 
significant reduction of Th1 and Th17 cell movement with lower mean velocity, 
meandering index and motility coefficient associated to higher arrest coefficient. 
We did not observe any significant difference between Th1 and Th17 movement 
and both subsets were moving slower when compared to the other disease phases.  
These data suggest that stationary T cells were engaged in contacts with APCs 
and that antigen-dependent phenomena contribute to disease progression. 
Previous TPLM studies have shown that migration of T cells is guided by stromal 
cells/extracellular matrixes (ECMs) exhibiting unique fibrous structures such as 
stromal cell networks (Bajénoff M et al., Immunity, 2006), and collagen fibers 
(Boissonnas A et al., J Exp Med, 2007). Leukocytes including T cells exhibit 
amoeboid migration and the three biomechanical factors determining this type of 
motility include: 1) integrin-mediated adhesion, 2) actin polymerization-driven 
leading edge protrusion, and 3) myosin II-mediated contractility (Lämmermann T 
et al., Curr Opin Cell Biol, 2009).  It is unclear whether stromal cell networks like 
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those found in the lymph nodes are also present in the CNS parenchyma, but 
activated T cells can move in a similar manner in the CNS and lymph nodes, 
suggesting analogous stromal structures are present in the CNS (Wilson EH et al., 
Immunity, 2009). Accordingly, TPLSM analysis in an experimental model of 
toxoplasmic encephalitis indicated the presence of a reticular system associated 
with areas of parasite replication and local CNS inflammation, but not in normal 
brain tissues (Wilson EH et al., Immunity, 2009). CD4+ T-cell motility is actively 
promoted in the spinal cord during EAE (Herz JM et al., J Neuroinflammation, 
2011), and CD4+ T cells can gain access to CNS parenchyma and partially 
migrate along inflammation-induced ECMs, which are similar to those seen in 
lymph nodes (Herz JM et al., J Neuroinflammation, 2011). These observations 
suggest that pre-existing scaffolds guide lymphocyte migration in lymphoid 
tissues, but specialized structures are induced during CNS inflammation and guide 
T cell migration, potentially facilitating the screening of APCs and integrating 
relevant stimulatory, costimulatory and regulatory signals (Wilson EH et al., 
Immunity, 2009; Herz JM et al., J Neuroinflammation, 2011).  
The molecular mechanisms controlling T cell motility within the inflamed CNS 
are poorly understood (Mrass P and Weninger W, Immunol Rev, 2006). In this 
context, we studied the role of integrins in both Th1 and Th17 cell migration into 
the SC parenchyma during EAE. Integrins are α-β-heterodimeric transmembrane 
glycoprotein receptors that mediate cell-ECM and cell-cell adhesion events 
through binding ECM proteins such as fibronectin. We used a TPLM approach to 
investigate the potential role of integrins in Th1 and Th17 cell dynamics during 
CNS inflammation. Blocking antibody anti-LFA-1 administration on the exposed 
SC at disease peak significantly altered the dynamics of Th1 and Th17 cells 
leading to a reduction in their velocity and motility. However, LFA-1 blockade 
differently modified the behavior of Th1 and Th17 cells. Th1 cells significantly 
reduced speed without stopping their movement and their directed migration in 
the parenchyma was profoundly altered after LFA-1 blockade. Also, the analysis 
of cellular morphology showed a drastic reduction in the volume and capacity of 
Th1 cells to extend cellular protrusions during their movement, suggesting that 
LFA-1 is actively involved in the cytoskeleton rearrangement necessary for Th1 
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cell amoeboid migration inside the inflamed CNS. LFA-1 blocking also 
drastically increased the number of not moving Th17 cells although the 
constrained migration of cells moving in the parenchyma was not affected by 
LFA-1 inhibition. Moreover, Th17 cells did not displayed morphological 
modifications in term of volume and number of vertices in both moving and not 
moving fractions ruling out the involvement of LFA-1 in cytoskeleton dynamics 
in Th17 cells. Together, these data suggest a different role of LFA-1 in the 
motility of Th1 compared to Th17 cells in the SC parenchyma during EAE and 
that LFA-1 is pivotal for T cell motility in the SC under inflammatory conditions 
at EAE peak.  
Notably, a4 integrin blockade had no role in Th1 cells motility, but drastically 
reduced the dynamics of Th17 cells inside the SC parenchyma leading to a 
significant decrease in the velocity of these cells. Importantly, the arrest 
coefficient was significantly higher after a4 integrin blockade suggesting that a 
great portion of cells completely stopped their movements. Overall, these data 
suggest a selective involvement for the a4 integrins in Th17 cell motility in the 
SC under inflammatory conditions at EAE peak. Future experiments are needed to 
clarify the contribution of a4b1 and a4b7 in Th1 and Th17 migration inside the 
SC during EAE. Interestingly, MAdCAM-1, the a4b7 ligand, has been reported to 
be expressed on astrocytes surrounding blood vessels and on dendritic cells 
potentially mediating T cell migration and costimulation inside the CNS 
(Cannella B, J Neuroimmunol, 1991; Szabo MC et al, J Immunol 1997; Lehnert K 
et al., Eur J Immunol 1998; Kanwar JR et al., Immunol Cell Biol, 2000).  
The inhibition of intra-tissue motility of activated T cells into CNS could 
represent a point of therapeutic intervention in autoimmune diseases of the CNS. 
An important result of our study was the significant impact of anti-LFA-1 or anti-
a4b7 antibodies intrathecal injection on EAE development. Our data clearly 
indicate that local administration of blocking anti-integrin antibodies after disease 
onset prevents EAE worsening, suggesting that interference with intra-CNS 
motility of activated T cells may represent a potential therapeutic approach in 
autoimmune diseases such as MS. However, integrin LFA-1 is involved in the 
generation of functional immunological synapse during antigen presentation in 
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secondary lymphoid organs and this process may also be important during T cell 
reactivation by CNS APCs (Kawakami N et al., J Exp Med, 2005; Springer TA et 
al., Curr Opin Cell Biol, 2012). Thus, we speculate that LFA-1 inhibition in the 
SC of EAE mice may limit not only T cell movement but also T cell reactivation 
in the CNS parenchyma. On the other hand, LFA-1 was shown to be also 
important for neuronal functionality, and to mediate direct T cell-neuron contacts 
through binding to neuronal ICAMs (Tian L et al., Blood, 2008; Dove A et al., 
Nat Biotechnol, 2000). In particular, using TPLM it was previously demonstrated 
that Th17 cells form synapse-like contacts with neurons in an LFA-1/ICAM-1 
dependent manner leading to neuronal dysfunction and axonal damage during 
EAE (Siffrin V et al., Immunity, 2010). LFA-1 binding is also implicated in the 
sequestration and accumulation of activated T cells in the leptomeningeal milieu, 
a crucial process leading to CNS invasion by leukocytes during EAE (Schläger 
CH et al., Nature, 2016). Therefore, we cannot exclude that anti-LFA-1 
intrathecal treatment may affect other immunological processes inside the CNS, 
like the motility and pathogenic behavior of other immune cell populations and 
immune-cell mediated neuronal damage, and further studies are required to clarify 
the of anti-LFA-1 treatment in CNS local inflammatory responses during EAE. In 
light of these considerations, further neuropathological investigations after anti 
integrin treatments will clarify the potential manifolds mechanisms at the basis of 
clinical disease amelioration. Indeed, the number of inflammatory infiltrates 
stained with hematoxylin/eosin was reduced probably due to a less activated 
milieu, including T cell reactivation blockade, that reduced the attraction of other 
pro-inflammatory immune components. Therefore, we don’t expect neither a 
reduction exclusively of infiltrating T cells nor an interference only with Th17 
cells. 
Integrins involved in leukocyte adhesion cascade (b1 and b2), have been proven 
to be valuable therapeutic targets in the treatment of several inflammatory and 
autoimmune diseases. Natalizumab was the first humanized monoclonal antibody 
targeting the a4-integrin subunit (Steinman L, Nat Rev Drugs Discov, 2005) 
approved by the Food and Drug Administration (FDA) for the treatment of MS 
and Crohn’s disease. The treatment with this drug caused severe side effects in 
 90 
some patients leading to the development of progressive multifocal 
leukoencephalopathy (PML) due to infection with JC virus (Yousry TA et al., N 
Engl J Med, 2006). Vedolizumab, a humanized anti a4b7 integrin antibody has 
recently emerged as efficient therapy for inflammatory bowel diseases with an 
excellent safety profile. Notably no cases of PML were reported in patients treated 
with Vedolizumab, suggesting this antibody, which acts more selectively on 
leukocyte trafficking has lower risk of PML compared to Natalizumab (Sands 
Bruce, Dig Dis, 2017). In recent years, several anti-LFA-1-inhibitory compounds 
with various structural motifs have been described in patent literature. Antibodies 
against LFA-1 have been developed for the treatment of ischemia and stroke, but 
the occurrence of severe side effects in late clinical phases lead to the 
discontinuation of several drug candidates (e.g., b2-targeting antibody Erlizumab) 
(Dove A et al., Nat Biotechnol, 2000). Efalizumab, an aL-selective antibody, 
previously approved by the FDA for the treatment of psoriasis, was removed in 
2009 from the market after several cases of PML (Woolacott H et al., Health 
Technol Assess, 2006). PML after anti-integrin treatment is due to the systemic 
immunosuppressive action of anti-integrin interfering with T cell trafficking 
necessary to fight against opportunistic infections. In the light of these 
considerations, intrathecal therapies may represent an efficient route of 
administration with lower risk of PML. Among side collateral effects of 
intrathecal route of administration, literature reports neurocognitive impairment in 
20-40% of survivors of childhood acute lymphoblastic leukemia after regional 
treatment with intrathecal Methotrexate (Krull KW et al., Leuk Lymphoma, 2013). 
The same intrathecal chemotherapy agent causes cognitive impairment in children 
with medulloblastoma (Riva D et al., Neurology, 2002. Notably, Methotrexate is 
the most well-known antifolate included in many cancer therapies, but its 
substantial toxicity impacts its wider use, especially in pediatric oncology. 
Recently, Pompe and coworkers assessed, in a preliminary study, the feasibility 
and toxicity of intraventricularly administered Methotrexate in children with 
infant and /or metastatic medulloblastoma. Interestingly, this other CNS regional 
treatment was feasible and mostly well tolerated, to date (Pompe RS et al., Eur J 
Cancer, 2015). Other alterations in CNS functions and social behavior after 
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intrathecal therapies do not emerge from recent literature. At the state of art, we 
suggest that intrathecal injection of therapies interfering with effector T cell 
dynamics in the CNS will not impair systemic immunity and may complement 
existing MS therapies leading to faster resolution of the CNS immune attack and 
potentially interfering with chronic disease course. 
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